Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001  
CONFIDENTIAL AND PROPRIETARY  1 of 78 Clinical Study Protocol Amendment 2 
Drug Substance  AZD4041  
Study Code  D7460C00001  
Version  3.0 
Date  15 June 2021 
 A Phase I , Randomi zed, Double -blind , Placebo -controlled Study to Assess 
the Safety, Tolerability, and Pharmacokinetics of AZD4041 Following Single 
Ascending Dose Administration to Healthy Volunteers  
Sponsor:  [COMPANY_008] AB, 151 85 Södertälje, Sweden  
Regulatory Agency Identifying Number(s):  IND [ADDRESS_1002546] procedures.  The Clinical Study Protocol Amendment 2 is publicly 
registered and the results are disclosed and/or published according to the [COMPANY_008] Global Policy on Bioethics and in compliance with prevailing laws and regulations. 
Clinical Study Protocol Amendment [ADDRESS_1002547] to change and revision.  
 
 

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041  - D7460C00001  
 
CONFIDENTIAL AND PROPRIETARY   5 of 78  
 TABLE OF CONTENTS  
TITLE PAGE ............................................................................................................................. 1  
VERSION HISTORY  ............................................................................................................... 2  
SPONSOR SIGNATURES  ....................................................................................................... 3  
SIGNATURE [CONTACT_241041] .................................................................. 4  
TABLE OF CONTENTS  .......................................................................................................... 5  
1 PROTOCOL SUMMARY  ..................................................................................... 9  
1.1 Schedule of Activities (SoA) .................................................................................. 9  
1.2 Synopsis ................................................................................................................ 12  
1.3 Schema  .................................................................................................................. 17  
2 INTRODUCTION  ................................................................................................ 18  
2.1 Study rationale ...................................................................................................... 19  
2.2 Benefit/risk assessment  ......................................................................................... 20  
 Benefit  .................................................................................................................. 20  
 Potential risks and mitigation strategies  ............................................................... 20  
 Benefit/risk conclusion  ......................................................................................... 24  
2.3 AZD4041 - D7460C00001 single ascending dose study - results as of 
18 March 2021 ...................................................................................................... 24  
3 OBJECTIVES AND ENDPOINTS  ...................................................................... 26  
4 STUDY DESIGN  ................................................................................................. 27  
4.1 Overall design  ....................................................................................................... 27  
 Overview  .............................................................................................................. 27  
4.2 Scientific rationale for study design ..................................................................... 27  
4.3 Justification for dose  ............................................................................................. 28  
4.4 End of study definition ......................................................................................... 30  
5 STUDY POPULATION  ....................................................................................... 30  
5.1 Inclusion criteria  ................................................................................................... 30  
5.2 Exclus ion criteria  .................................................................................................. 31  
5.3 Lifestyle restrictions  ............................................................................................. 33  
 Meals and dietary restrictions  ............................................................................... 33  
 Caffeine, alcohol, and tobacco  ............................................................................. 34  
 Activity  ................................................................................................................. 34  
5.4 Screen failures  ...................................................................................................... 34  
6 STUDY TREATMENTS ..................................................................................... 34  
6.1 Treatments administered  ....................................................................................... 35  
 Investigational products  ........................................................................................ 35  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041  - D7460C00001  
 
CONFIDENTIAL AND PROPRIETARY   6 of 78  
 6.2 Preparation/handling/storage/accountability  ........................................................ 35  
6.3 Measures to minimize bias: randomization and blinding ..................................... [ADDRESS_1002548] to follow -up .................................................................................................. 39  
7.3 Withdrawal from the study  ................................................................................... 40  
8 STUDY ASSESSMENTS AN D PROCEDURES  ............................................... 40  
8.1 Efficacy assessments (not applicable)  .................................................................. 41  
8.2 Safety assessments  ................................................................................................ 41  
 Clinical safety laboratory assessments  ................................................................. 41  
 Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone, and 
inhibin B assessments ........................................................................................... 43  
 Physical exami nations  .......................................................................................... 43  
 Vital signs  ............................................................................................................. 43  
 Electrocar diograms  ............................................................................................... 43  
[IP_ADDRESS]  Resting 12- lead ECG  ............................................................................................ 44  
[IP_ADDRESS]  Electronic capture and analysis of 12- lead digital ECGs  ..................................... 44  
[IP_ADDRESS]  Telemetry (real -time display)  ............................................................................... 47  
8.3 Collection of adverse events  ................................................................................. 47  
 Method of detecting AEs and SAEs  ..................................................................... 47  
 Time period and frequency for collecting AE and SAE information  ................... 47  
 Follow-up of AEs and SAEs  ................................................................................ 48  
 Adverse event data collection  ............................................................................... 48  
 Causality collection  .............................................................................................. 49  
 Adverse events based on signs and symptoms  ..................................................... 49  
 Adverse events based on examinations and tests  ................................................. 49  
 Hy’s Law  .............................................................................................................. 50  
8.4 Safety reporting and medical management .......................................................... 50  
 Reporting of serious adverse events  ..................................................................... 50  
 Pregnancy  ............................................................................................................. 50  
[IP_ADDRESS]  Maternal exposure  ................................................................................................ 50  
[IP_ADDRESS]  Paternal exposure .................................................................................................. 51  
 Overdose  ............................................................................................................... 51  
 Medication error  ................................................................................................... 52  
 Management of IP -related toxicities  ..................................................................... 52  
 Safety Review Committee .................................................................................... 53  
8.5 Pharmacokinetics .................................................................................................. 54  
 Determination of drug concentration  .................................................................... 54  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041  - D7460C00001  
 
CONFIDENTIAL AND PROPRIETARY   7 of 78  
 
 Metabolite identification in plasma  ...................................................................... 55  
 Storage and destruction of pharmacokinetic samples  ........................................... 55  
8.6 Pharmacodynamics ............................................................................................... 55  
9 STATISTICAL CONSIDER ATIONS  ................................................................. 55  
9.1 Statistical hypotheses  ............................................................................................ 56  
9.2 Sample size determination  .................................................................................... 56  
9.3 Populations for analyses  ....................................................................................... 56  
9.4 Statistical analyses  ................................................................................................ 56  
 Pharmacokinetic analyses ..................................................................................... 56  
 Safety analyses  ..................................................................................................... 57  
[IP_ADDRESS]  Safety and tolerability  ........................................................................................... 57  
[IP_ADDRESS]  Pharmacokinetics .................................................................................................. [ADDRESS_1002549] OF TABLES  
Table  1 Schedule of Activities - Cohorts 1 to 3 ......................................................... 9  
Table  2 Schedule of Activities - Cohorts 4 to 6 ....................................................... 11  
Table 3  Unbound exposure margins to the 100 mg/kg PO dog CV study exposure [ADDRESS_1002550] OF FIGURES  
Figure 1 Study design (Cohorts 1 to 3) ...................................................................... 17  
Figure 2 Study design (Cohorts 4 to 6) ...................................................................... [ADDRESS_1002551] OF APPENDICES  
Appendix  A Regulatory, ethical and study oversight considerations .............................. 62  
Appendix  B Adverse event definitions and additional safety information ..................... 66  
Appendix  C Actions required in cases of increases in liver biochemistry and 
evaluation of Hy’s Law ............................................................................... 71  
Appendix  D Abbreviations .............................................................................................. 76  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001  
CONFIDENTIAL AND PROPRIETARY  9 of 78 1 PROTOCOL SUMMARY  
1.1 Schedule of Activities (SoA)  
Table 1 Schedule of Activities - Cohorts 1 to 3 
Screening  
Day -28 to 
Day -2 Day -1 Day 1  Day 2  Day 3  Follow –up 
Visita 
([ADDRESS_1002552]-dose)  
Informed consent  X 
Inclusion/exclusion criteria  X X X 
Demographic data  X 
Medical history  X 
Urinary drug screen  X X 
Alcohol screen  X X 
Testing for HIV, hepatitis B and C  X 
Pregnancy testingbX X 
FSH testing in women  X 
Randomization  X 
Admission to CRU  X 
Discharge from CRU  X 
Height, body weight, and BMIcX X X X 
Study drug administration  X 
Adverse event recording  X X X X X X 
Blood pressure, temperature, 
respi[INVESTIGATOR_697], and pulse rate  X X Xd X X X 
12-lead paper safety ECG X X Xe Xe Xe 
12-lead digital ECG Xe Xe Xe 
TelemetryfX X 
Clinical laboratory evaluationsg X X X X 
Physical examination X X X X 
Blood sampling for PKhX X X 
aTests will be per formed at follow -up and also in cases of discontinuation . 
bSerum pregnancy test  wil l be performed  at screening and check -in. 
cHeight will be measured at screening only . 
dBlood pressure, temperature, respi[INVESTIGATOR_697], and pulse rate will be measured at pre -dos e, then at 1, 2, 3, 4, 
6, 8, 12, 24, and [ADDRESS_1002553] collected more than 2 weeks before dosing . 
h Blood samples will be collected at p re-dose, then at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours . 
BMI  body mass index; CRU  Clinical Research Unit; ECG  electr ocardiogram; FSH  follicle stimulating 
hormone; HIV  human immunodeficiency virus; PK  pharmacokinetic(s)  
 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  11 of 78  
 Table 2 Schedule of Activities  - Cohorts 4 to 6 
 Screening  
Day -28 to  
Day -2 Day -2 Day -1 Day 1  Day 2  Day 3  Day 4  Follow –up 
Visita 
(14±[ADDRESS_1002554]-dose)  
Informed consent  X        
Inclusion/exclusion criteria  X  X X     
Demographic data  X        
Medical history  X        
Urinary drug screen  X  X      
Alcohol screen  X  X      
Testing for HIV, hepatitis B  
and C  X        
Pregnancy testingb X  X      
FSH testing in women  X        
Randomization     X     
Admission to CRU   X       
Discharge from CRU        X  
Height, body weight, and 
BMIc X  X    X X 
Study drug administration     X     
Adverse event recording  X X X X X X X X 
Blood pressure, temperature, 
respi[INVESTIGATOR_697], and pulse rate  X  X Xd X X X X 
12-lead paper safety ECG  X  X Xe Xe Xe Xe  
12-lead digital ECG     Xe Xe Xe Xe  
Telemetryf   X X     
Clinical laboratory 
evaluationsg X  X  X   X 
Physical examination  X  X    X X 
Blood sampling for PKh    X X X X  
Blood sampling for 
testosterone, LH, FSH, and 
inhibin B  (male subjects only)i   X X X X X  
a Tests will be performed at follow -up and also in cases of discontinuation . 
b Serum pregnancy test will be performed at screening and check -in. 
c Height will be measured at screening only . 
Clinical Study Protocol Amendment [ADDRESS_1002555] 5 subjects in Cohort  5: Telemetry for [ADDRESS_1002556] -dose.  For the remaining subjects in Cohort  5 and all 
subjects in Cohort  6: Telemetry for [ADDRESS_1002557] collected more than 2 weeks before dosing . 
h Blood samples will be collected at p re-dose, then at 0.25,  0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 
72 hours. 
i Male subjects only: samples for t estosterone, LH, FSH , and inhibin B will be collected at 0 hour (0800 or 
1000 ) and at  4, 6, 8, 12, 22, and 24 hours  on Day -1 and at 0 hour (0800 or 1000) and at  1, 2, 4, 6, 8, 12, 24, 
36, 48, and 72 hours on Day 1  to Day 3 .  The ‘0’ hour time point should be approximately the same time 
that dosing is scheduled for on Day 1.  On Day 1, sam ples for testosterone, LH, FSH , and inhibin B will be 
collected at the same time as PK samples . 
BMI  body mass index; CRU  Clinical Research Unit ; ECG  electrocardiogram; FSH  follicle stimulating 
hormone; HIV  human immunodeficiency virus; LH  luteinizing h ormone; PK  pharmacokinetic(s)  
 
1.2 Synopsis  
Protocol title:  
A Phase I , randomiz ed, double-blind, placebo -controlled study to a ssess the safety, 
tolerability, and pharmacokinetics of AZD4041 f ollowing single ascending dose 
administration to healthy volunteers 
Rationale:  
It is predicted that approximately 0.6 billion current smokers worldwide will die from 
smoking-related illnesses, such as chronic obstructive pulmonary disease, cardiovascular 
disease, and lung cancer ( Ezzati and Lopez 2003, Doll et al 2004, Coe et al 2005, Mathers and 
Loncar 2006) .  If current trends in tobacco use persist, by 2020, smoking will become the 
largest single health problem worldwide, causing approximately 8.4 million deaths annually 
(Murray and Lopez 1997 ).  Smokers who quit before the onset of tobacco- related illness can 
largely avoid the increased mortality risk ( Doll et al 1994, Peto et al 2000) .  Nevertheless, 
approxi
mately 80% of smokers currently attempting to quit will relapse within the first month 
of abstinence (Benowitz 2009).  The development of more efficacious smoking cessation aids 
is perhaps the most cost- effective intervention possible within a health -care system (Knight et 
al 2009).  Although clinically efficacious, current smoking cessation agents have limited utility .  In smokers attempting to quit, approximately 23% treated with Chantix
® (varenicline)  
and approximately 16% treated with Zyban (bupropi[INVESTIGATOR_2394]) remain abstinent after 1  year, 
compared with approximately 9% of those treated with placebo ( Knight et al 2009).  
Pharmacotherapy is therefore an effective strategy to ai d smoking cessation efforts, but there 
is considerable risk of relapse even when treated with the most efficacious medications currently available.  Further, medications that are effective aids to smoking cessation are 
Clinical Study Protocol Amendment [ADDRESS_1002558] of neuropsychiatric side effects, 
including changes in behavior, psychosis, anxiety, etc, and the use of varenicline may impair a person’s ability to drive or use machines ( eMC 2018).  Bupropi[INVESTIGATOR_2394], on the other hand, is 
associated with insomnia, dry mouth, and nausea ( Cahill et al 2011).  These adverse effects 
may lead to premature discontinuation of these medications, leading to relapse ( Catz et al 
2011).  This highlights the pressing need to develop safer and more effective smoking 
cessation therapeutics.  
The neuropeptides orexin A and orexin B (also known as hypocretin 1 and hypocretin 2, respectively) are hypothalamic neuropeptides  that act through 2 closely related 
G protein-coupled receptors (GPCRs), the orexin 1 (OX1) and orexin 2 (OX2) receptors.  Orexin A has high affinity for both receptors whereas orexin B has higher affinity for OX2 over OX1 receptors.  Orexin transmission h as been implicated in a diverse range of 
physiological functions , including feeding and energy homeostasis ( Sakurai et al 1998), the 
sleep/wake cycle (Willie et al 2003 ; Gotter et al 2016 ), neuroendocrine homeostasis, 
cardiovascular functions ( Samson et al 2007), and motivated behaviors ( Kodadek and Cai 
2010).   Nicotine, which is the principal reinforcing component in tobacco smoke responsible 
for addiction ( Stolerman and Jarvis 1995), activates orexin (hypocretin) neurons in the brain .  
This increase in orexinergic transmission is thought to play a crucial role in regulating the motivational properties of the drug that results in tobacco dependence ( Kenny 2011).  Further, 
OX1 receptors regulate the reinstatement of extinguished drug-seeking responses in abstinent rats (Boutrel et al 2005, Harris et al 2005 , Kenny 2011) and mice, considered animal model s 
with heuristic value for understanding relapse in abstinent human drug addicts.  As such, OX1 receptor antagonists are considered one of the most promising novel therapeutic strategies to facilitate smoking cessation .  Importantly, OX1 receptors play a similar role in regulating the 
addiction-related actions of opi[INVESTIGATOR_2438], psychomotor stimulants and alcohol, raising the 
possibility that OX1 receptor antagonists m ay have utility for the treatment of addiction across 
different classes of abused drugs. 
[COMPANY_008], in partnership with Eolas Therapeutics, Inc, has developed an OX1 receptor 
antagonist, AZD4041, which demonstrates favorable drug-like physiochemical properties .  
The high level of selectivity  of AZD4041 between the OX1 and OX2 receptors substantially 
reduces the potential for hypnotic effects of this OX1 antagonist since it is thought that the OX2 receptor is primarily responsible for the effects of orexin on sleep /wake transitions and 
maintenance of sleep states  (Boutrel et al 2005).  Consistent with this possibility, AZD4041 
does not induce sleep- like electroencephalogram ( EEG ) waveforms in rodents across a broad 
range of doses .  AZD4041 does not measurably inhibit the activity of cytochrome P450 
enzymes or cardiac potassium ion channels ( hERG ) nor does it have significant actions at any 
non-OX1 receptor targets so far screened .  AZD4041 is highly brain penetrant in non-human 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  14 of 78  
 primates, and has relatively slow rates of cle arance and high levels of oral bioavailability in 
dogs.  AZD4041 demonstrates in vivo efficacy in rodents  and non- human primates  at 
relatively low exposures . 
Objectives and endpoints : 
Objectives  Endpoint/variable:  
Primary objective:  
To assess the safety  and tolerability of AZD4041 
following oral administration of single ascending 
doses  • Adverse events  
• Vital signs  
• Hematology , biochemistry, and urinalysis  
• ECG (12 -lead and telemetry)  
• Testosterone, LH, FSH, and inhibin B (male 
subjects only)  
Secondary object ives:   
To characteri ze the pharmacokinetics of AZD4041 
following oral administration of single ascending 
doses of AZD4041  • Cmax 
• Tmax 
• AUC 0-t 
• AUC 0-inf 
• t1/2λz 
• CL/F  
• Vss/F 
Exploratory objectives   
Characterize the pharmacodynamic relationship between drug exposure and QT interval  An exposure –response (E -R) analysis may be 
conducted with data from this study alone or in combination with other studies as appropriate, with a 
pre-specified workflow described in a separate 
technical document, for the QT interval  corrected for 
heart rate using Fridericia’s formula (QTcF) 
parameter, as part of the cardiac safety evaluation and with the intention to obtain a Thorough QT (TQT) 
study substitute.   The result of the E -R analysis may 
not be included in the main study rep ort. 
AUC 0-t  Area under the curve from time 0 to time t; AUC 0-inf  Extrapolation of the area under the curve from time 
0 to infinity; CL/F  Apparent total clearance of the drug from plasma after oral administration; C max  Maximum 
(peak) plasma drug concentration; ECG  Electrocardiogram; E-R  Exposure -response; FSH  Follicle stimulating 
hormone; LH  Luteinizing hormone ; QTcF  QT interval corrected for heart rate using Fridericia’s formula; 
t1/2λz  Terminal half-life; Tmax  Time to reach maximum (peak) plasma concentration following drug 
administration; V ss/F  Apparent volume of distribution at steady state after non -intravenous administration  
 
Overall design:  
This is a Phase I, first -in-human (FIH), single- center , randomized, double-blind, 
placebo -controlled, single ascending dose, sequential group study in healthy vasectomized 
male and female subjects of non -childbearing potential, aged 18 to 55 years.  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  15 of 78  
 Study period:  
Estimated date of first subject  enrolled: Q3/[ADDRESS_1002559]  completed: Q4/2021 
Number of subjec ts: 
The study plans to enroll [ADDRESS_1002560] will be randomized to receive AZD4041 in a blinded fashion.  
Treatments and treatment duration:  
The study comprises a screening period of up to 28 days (4 weeks), a 4- day in -patient  period 
for Cohorts 1 to 3 and a 6- day in -patient period for Cohorts 4 to 6 during which a single oral 
dose of AZD4041 or placebo will be administered, and an out- patient  follow -up period.  The 
overall study duration (screening, treatment, and follow-up periods) will therefore be 
approximately [ADDRESS_1002561] level (NOAEL) exposure from the [ADDRESS_1002562] been dosed   
Given that the exposure limits are predicted to be reached at , only vasectomised 
male and female subjects of non -childbearing potential will be enrolled i n the remaining 
cohorts (Cohort 4 onwards).  The highest dose that could be explored in these remaining cohorts will be determined by [CONTACT_733741], from the 28-day repeat dose toxicity study. 
The safety data from the sentinel subjects up to [ADDRESS_1002563]- dose will be reviewed by [CONTACT_1268] (PI), C linical Research Organization ( CRO ) Medical Monitor, and 
[COMPANY_008] Study Physician  before the remaining subjects in the cohort are dosed.  The 
remai ning [ADDRESS_1002564] 24 hours after the sentinel cohort. 
Safety review  committee  
A Safety Review Committee (SRC) will review data from each cohort before progression to 
the next cohort occurs. 

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  16 of 78  
 Statistical methods  
Safety, tolerability , and pharmacokinetic ( PK) data will be summariz ed descriptively as 
appropriate.  Descriptive summary statistics for continuous variables will include number, 
arithmetic mean, standard deviation, minimum, median, and maximum, while for continuous 
PK variables, descriptive summary statistics will also include geometric mean and arithmetic coefficient of variation .  Descriptive summary statistics for categorical data will include 
frequency and proportion.  Tests of significance of group difference (drug dose versus 
placebo) on change from baseline in safety variables will also be performed .  Model- based 
approaches will be used, if appropriate. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  17 of 78  
 1.3 Schema  
The general study design is summarized in F igure 1 (Cohorts 1 to 3) and Figure 2 (Cohorts 4 
to 6). 
Figure 1 Study design  (Cohorts 1 to 3) 
Cohort timing  
 
   
 
 
Figure 2 Study design (Cohort s 4 to 6) 
Cohort timing  
 
   
 
 Screening/  
enrollment visit  Randomization 
and dosing  Follow -up 
visit 
Admission 
to the unit  Discharge 
from the unit  
In-patient period  Day -[ADDRESS_1002565] -dose 
Screening 
period  
Screening/  
enrollment visit  Randomization 
and dosing  Follow -up 
visit 
Admission 
to the unit  Discharge 
from the unit  
In-patient period  Day -[ADDRESS_1002566] -dose 
Screening 
period  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  18 of 78  
 2 INTRODUCTION 
Smoking is an epi[INVESTIGATOR_733726].  It is the leading cause of morbidity and 
mortality in virtually every country in the world ( Lim et al 2010 ).  Smoking increases the risk 
of death by [CONTACT_14774]-fold in smokers, compared with non-smokers ( Jha et al 2013 ).  It is predicted 
that approximately 0.6 billion current smokers worldwide will die from smoking- related 
illnesses, such as chronic obstructive pulmonary disease, cardiovascular disease and lung cancer ( Ezzati and Lopez 2003, Doll et al 2004, Coe et al 2005, Mathers and Loncar 2006 ).  If 
current trends in tobacco use persist, by 2020, smoking wi ll become the largest single health 
problem worldwide, causing approximately 8.4 million deaths annually ( Murray and Lopez 
1997).  Smokers who quit before the onset of tobacco -related illness can largely avoid the 
increased mortality risk ( Doll et al 1994, Peto et al 2000).  Nevertheless, approximately 80% 
of smokers currently attempting to quit will relapse within the first month of abstinence 
(Benowitz 2009).   
The smoking epi[INVESTIGATOR_733727] a great cost to society .  It is estimated that the total 
economic cost of smoking resulting from health -care expenditures and loss of productivity 
totalled 1.8% of the world’s annual gross domestic product, equivalent to US$1436 billion (Goodchild et al 2018).  
The development of more efficacious smoking cessation aids is perhaps the most 
cost-effective intervention possible within a health -care system ( Knight et al 2009).  Although 
clinically efficacious, current smoking cessation agents have limited utility .  In smokers 
attempting to quit, approximately 23% treated with Chantix (varenicline)  and approximately  
16% treated with Zyban  (bupropi[INVESTIGATOR_2394]) remain abstinent after 1 year, compared with 
approximately 9% of those treated with placebo ( Knight et al 2009).  Pharmacotherapy is 
therefore an effective strategy to aid smoking cessation efforts, but there is considerable risk 
of relapse even when treated with the most efficacious medications currently available.  Further , medications that are effective aids to smoking cessation are associated with a range of 
adverse effects .  For example, varenicline, the most effective medication in this category, is 
associated with a host of neuropsychiatric side effects , including changes in behavior, 
psychosis, anxiety, etc, and the use of varenic line may impair a person’s ability to drive or use 
machines ( eMC 2018).  Bupropi[INVESTIGATOR_2394], on the other hand, is associated with insomnia, dry mouth, 
and nausea ( Cahill et al 2011 ).  These adverse effects may lead to premature discontinuation 
of these medications, leading to relapse ( Catz et al 2011).  This highlights the significant 
unme t need to develop safer and more effective smoking cessation therapeutics. 
The neuropeptides orexin A and orexin B (also known as hypocretin 1 and hypocretin 2, respectively) are hypothalamic neuropeptides that act through 2 closely related G protein 
coupled receptors (G PCRs ), the OX1 and OX2 receptors.  Orexin A has high affinity for both 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  19 of 78  
 receptors whereas orexin B has higher affinity for OX2 over OX1 receptors.  Orexin 
transmission has been implicated in a diverse range of physiological functions, in cluding 
feeding and energy homeostasis ( Sakurai et al 1998 ), the sleep/wake cycle ( Willie et al 2003 ; 
Gotter et al 2016), neuroendocrine homeostasis, cardiovascular functions ( Samson et al 2007), 
and motivated behaviors ( Kodadek and Cai 2010) .  The OX1 receptor signals almost 
exclusively through Gq coupling.  Nicotine, which is the principal reinforcing component in tobacco smoke responsible for addiction ( Stole rman and Jarvis 1995), activates orexin 
(hypocretin) neurons in the brain.  This increase in orexinergic transmission is thought to play 
a crucial role in regulating the motivational properties of the drug that results in tobacco dependence ( Kenny 2011 ).  Further, OX1 receptors regulate the reinstatement of extinguished 
drug-seeking responses in abstinent ra ts (Boutrel et al 2005, Harris et al 2005 , Kenny  2011) 
and mice, considered animal models with heuristic value for understanding relapse in abstinent human drug addicts.  As such, OX1 receptor antagonists are considered one of the most promising novel therapeutic strategies to facilitate smoking cessation .  Importantly, OX1 
receptors play a similar role in regulating the addiction -related actions of opi[INVESTIGATOR_2438], 
psychomotor stimulants and alcohol, raising the possibility that OX1 receptor antagonists may have utility for the treatment of addiction across different classes of abused drugs. 
2.[ADDRESS_1002567] since 
it is thought that the OX2 receptor is primarily responsible for the effects of orexin on arousal (Boutrel et al 2005).  Consistent with this possibility, AZD4041 does not induce sleep- like 
EEG waveforms in rodents across a broad range of doses.   
 
 
 
 
  
Further details of these studies are provided in the Investigator’ s Brochure.  
AZD4041 may therefore provide an attractive treatment option as a treatment for smoking cessation.  
This study is being conducted to assess the safety, tolerability and PK of single doses of 
AZD4041 in a small number of healthy subjects, prior to advancing AZD4041 into larger clinical trials of longer duration.  

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  20 of 78  
 2.2 Benefit/risk assessment  
 Benefit 
AZD4041 has shown significant efficacy in the nicotine self- administration studies in rats  and 
monkeys.  These models are well established with drugs effective in smoking cessation ; eg, 
varenicline, showing efficacy in these experiments  (O’Connor et al 2010) .  AZD4041 was 
effective in a dose -dependent manner in blocking the withdrawal-induced nicotine- seeking  
response in the rat withdrawal model.  Extrapolation of IC 50 or in vivo 90% inhibitory 
concentration ( IC90) in the rat withdrawal model data with AZD4041 indicates that the 
target -free central nervous system  exposure between  , respectively, would 
be required for human efficacy.  
It therefore appears that AZD4041 could represent a novel strategy in the treatment of 
addictive disorders such as smoking cessation, where it has the potential to address a significant unmet need.  
The healthy volunteers who participate in this study are not expected to benefit from 
AZD4041. 
 Potential risks and mitigation strategies 
There is no prior clinical information for AZD4041, as this is the FIH study.  While a dual 
orexin receptor antagonist (suvorexant) is approved for the treatment of insomnia, no selective OX1  receptor antagonists have been approved for any indication so far.  Limited safety data 
are available for the single and multiple dosing studies with 2 selective OX1  receptor 
antagonists (ACT-539313 [ Kaufmann et al 2019] and JNJ-61393215 [ Salvadore et al 2019 ]).  
Both appeared to be well- tolerated in these initial studies with the most common reported 
adverse events (AEs) being somnolence and headache.  Thus, there is limited class 
information on the safety of this mechanism in humans.  Therefore, the starting dose will be 
selected such that the predicted exposures at this dose are several fold lower than the lowest 
predicted efficacious dose (see Section 4.3).  
In nonclinical  studies, AZD4041 has been evaluated in repeat dose toxicity studies of [ADDRESS_1002568] also been conducted.  
AZD4041 was negative in the Good Laboratory Practice (GLP) study in vitro Ames and 
chromosome aberration studies, and the GLP in vivo micronucleus study.  AZD4041 was also 
negative in an in vitro 3T3 phototoxicity assay. 

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  21 of 78  
 No significant effects of AZD4041 were noted on the central nervous system, locomotor 
function or motor coordination in rats.  In the sleep /wake and EEG study in rats, AZD4041 
significantly increased wakefulness at the expense of  non-rapid eye movement ( NREM ) sleep 
when compared with control.   
 
  In this study, any effects on 
sleep /wakefulness will be assessed via AE reporting .  Only healthy volunteers will be enrolled 
in this  FIH study and any subject with a disease of the respi[INVESTIGATOR_733728] .  
Further, vital signs, including respi[INVESTIGATOR_697] (RR),  will be assessed at regular intervals after 
dosing (See Schedule of Activities  [SoA], Table 1 and Table 2).  
In the hERG assay, the .  In a panel of in 
vit
ro electrophysiological assays of recombinant human voltage- gated cardiac ion channels 
(hKv4.3/hKChIP2.2 – ITO; hKv7.1/hKCNE1 – IKS; hNav1.5 – INa; hKV1.5; hCav3.2; 
hHCN4) - AZD4041 had no activity.  Therefore, a risk of QT prolongation is not expected 
with AZD4041.  In the dog cardiovascular study, sustained durations of premature ventricular contractions, beginning approximately 7 hours after dosing and continuing up to 24 hours after dosing, .  The onset of the 
changes was soon after the approximate T
max  in the dog study.  Hemodynamic 
parameters were largely unaltered and were maintained in the physiological range of heart rate and blood pressure. In a dog 14- day investigative study, lower heart rate, with associated 
higher PR and QT intervals were recorded at ; there were no changes in the rate-
corrected QT interval  and no arrhythmias were noted .  There were no changes in ECG rhythm 
or waveform morphology attributable to AZD4041.  Furthermore, there were no effects on ECG parameters or morphology in a 28-day dog study in which dogs received up to 
. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  22 of 78  
  
 
 
 
 
 
Ta
ble 3  
 
   
  
  
  
 
 
 
      
      
      
      
      
 
CV  Cardiovascular; PO  Oral  
 
While it is unclear what physiological mechanisms could be responsible for the observed 
arrhythmias , further risk mitigation measures are be ing added to the protocol in the form of 
extend ing the pre -dose telemetry for [ADDRESS_1002569] 48 hours after dosing, in addition to the regular monitoring for heart rate (HR) and blood 
pressure (BP) .  Subjects older than 55 years will be excluded in order to reduce the risk of 
observing benign background arrhythmic events, which are typi[INVESTIGATOR_733729].  Stoppi[INVESTIGATOR_733730] (ECG) Q-T interval ( QTc), HR and BP  
have been included in this FIH  study.  
In the 28-day GLP tox icity studies, the key findings were lower thymus weights  and thymic 
atrophy in female dogs, and effects on the male reproductive tract in dogs.  Other findings were increased liver weight, attributed to hepatocellular hypertrophy in rats and dogs; and increased thyroid weight, attributed to follicular cell hypertrophy  and recorded in rats only.  
Due to the minimal severity and adaptive nature of the changes , the hepatic and thyroid 
changes were considered not adverse.  Lower thymus weights were noted for female dogs and correlated with increased severity of thymic atrophy , characteri zed by [CONTACT_733742], at the high  dose.  T aken together , the effect on thymus 
weight  combined with the microscopic finding  of atrophy  was considered to be adverse.  

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  23 of 78  
 There were no effects on organ weight or microscopic pathology noted for the thymus at the 
end of the recovery period, indic ating recovery.  
In the dog, effects in the form of tubular degeneration/atrophy of the testes, reduced luminal 
sperm in the epi[INVESTIGATOR_733731]/or single cell necrosis of the prostate glands, with associated effects on organ weight, were noted.  There was some evidence of recovery at the end of the 4-week recovery period, in that findings were of a lesser severity compared to 
the main test and/or of a similar incidence/severity to the concurrent controls .  There is some 
evidence that OX1  receptors are expressed in dog seminiferous tubules ( Ligouri et al 2018) 
and that orexin A is involved in the regulation of spermatogenesis ( Barreiro  et al 2005, 
Hakovirta et al 1999, Yan et al 1999, Yan et al 2000), which may demonstrate a potential link between the pharmacological action of AZD4041 and the findings in the dog.  The low dose in 
male  dogs was identified as the  NOAEL .  It should be noted t hat similar findings were not 
seen after [ADDRESS_1002570] dose that could be explored in these remaining cohorts will be determined by [CONTACT_733741], from the 28-day repe at dose toxicity study  
. 
In 
addition to the above risk mitigation strategies, a number of other measures are being taken 
in this study to minimiz e any potential risk to participants, giv en that th is is a n FIH  
administration of this compound.  The key measures among these include the following:  
• This study will employ sentinel dosing, whereby [INVESTIGATOR_13701] 2 subjects (1 active + 1 placebo) 
will be dosed in a blinded manner at the start of a cohort and their safety will be 
monitored for [ADDRESS_1002571] of the cohort; 
• Further, this study will enroll only healthy non- smokers who will be carefully selected 
based on exhaustive inclusion and exclusion criteria to avoid placing such subjects at any significant risk;  
• In addition, subjects will be confined to an in -patient unit that specializes in and is 
equipped for the conduct of FIH  studies, starting from the day prior to dosing and for 
72 hours after dosing. 
 

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  24 of 78  
 
 Benefit/risk conclusion 
The hepatic and thyroid effects were considered minimal , and adaptive and thymic atrophy 
fully recovered at the end of the recovery period.  Effects on respi[INVESTIGATOR_733732] , and ECGs will be used to comprehensively monitor any 
potential arrhythmic effect. The addition of risk mitigation measures in the form of extended 
telemetry and exclusion of subjects with abnormal pre-dose telemetry  indicating a high risk of 
arrhythmia events , extension of post-dose telemetry and reduction in the upper age limit for 
eligible subjects,  is considered adequate to address a potential risk of NS VT in the study 
population.  In fertile (non -vasectomised) males , the dose- limiting toxicity was considered to 
be the testicular findings in the dog.  Therefore, dosing in this study was restricted to a dose 
that was predicted to provide an exposure that was 10-fold below the NOAEL exposures in 
the Dog 28- day study  
 However, for cohorts 
wh
ere exposures are predicted to exceed the 10 -fold margin below the Dog 28- day study 
NOAEL and therefore  only vasectomised males or females of non -childbearing potential are 
being enrolled (C ohort 4 onwards), dosing will be limited by [CONTACT_733743], in the Dog 28-day study.  Therefore, the revised exposure limits for these cohorts are 
proposed not to exceed a free , whi ch 
correspond to the intermediate dose NOAEL exposures in the female dog at . 
Based on this information regarding the risks of AZD4041 and the precautions included in this 
first clinical study, the risks are considered acceptable in relation to the significant unmet need 
in subjects attempting to quit smoking.  
More detailed informa tion about the known and expected benefits and risks and reasonably 
expected AEs of AZD4041 may be found in the Investigator’s Brochure. 
2.[ADDRESS_1002572] completed dosing and 15-day follow-up (Study AZD4041 - D7460C00001).  The doses tested in Cohorts 1, 2, 3, and 4 were , respectively.  The 5
th cohort is 
partial ly completed (5 of 8 subjects) at an oral dose level of . 
   
  
 
  
 

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  25 of 78  
    
  
For
 cohorts 1, 2 and 3 the predicted exposure was planned not exceed a limit that is 
approximately 10-fold below the NOAEL exposures in males in the Dog 28-day study 
(Table 4).  Subsequent cohorts in female s of non-childbearing potential and vasectomised 
males have revised exposure limits that is  proposed not to exceed the intermediate dose 
NOAEL exposures in the female dog at .  Utiliz ing geometric mean data, 
observed exposures at  provide a margin to free C max and an  
margin to free AUC 0-inf when compared to the female dog NOAEL derived from the 28 Day 
GLP toxicology study ( Table 5).  For the partial Cohort 5 data at  geometric mean data 
indicates a  margin to free C max and an  margin to free AUC 0-inf when the same 
comparison is made to the female dog NOAEL exposures. 
Table  4 Observed exposures and margins to male dog NOAEL  
Clinical 
dose  
(mg)  Human 
free C max 
(ng/mL)  Human free 
Cmax/Dose  Cmax 
margin to 
male dog 
NOAEL  Human free 
AUC 0-inf 
(ng·h/mL)  Human free 
AUC 0-inf/Dose  AUC 0-inf 
margin to 
male dog  
NOAEL  
       
       
       
AUC 0-inf  Extrapolation of the  area under the curve from time 0 to infinity; C max  Maximum (peak) plasma drug 
concentration; NOAEL   No-observed -adverse -effect level  
n/a = not applicable since male dog NOAEL was not util ized as exposure limit beyond Cohort 3 
Note: Exposures are provided as geometric means (n=6) . 
 
Pharmacokinetic data within cohorts indicated that there was some variability in systemic 
exposure between individuals.  As an example in Cohort 3, the coefficient of variation for 
Cmax geometric mean was 24.7% and the coefficient of variation for AUC 0-inf geometric mean 
was 43.7%.  For 3 subjects within  Cohort 3, extrapolation of AUC 0-inf following 
noncompartmental analysis was >20% , indicating some uncertainty in the calculation of this 
parameter.  However, with an extended sampling period and extrapolation of AUC 0-inf  
following noncompartmental analysis of <20% in all subjects, variability in systemic exposure 
was still evident in Cohort 4, as exemplified by a coefficient of variation for C max geometric 
mean of 21.2% and a coefficient of variation for AUC 0-inf geometric mean of 52.4%. 
Linear regression modelling with a linear scale has been employed to understand the 
relationship between C max and AUC 0-inf.  Utili zing predicted exposures from the linear 
regression model, doses of  and higher are expected to have a  margin to the 

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  26 of 78  
 female dog NOAEL, for Cmax and AUC 0-inf (Table  5).  This modelling and the projected 
system ic exposures will be revised as additional PK  data becomes available.   The SRC will 
evaluate the safety, tolerability, and PK of AZD4041 and determine the next dose.  The dose 
level for a given cohort will be referenced from the applicable safety summary meeting minutes.  
Table  5 Predicted exposures and margins to NOAEL  
Clinical dose  
(mg)  Human free 
Cmax (ng/mL)  Human free AUC 0-inf 
(ng·h/mL)  Cmax margin to 
female dog  
NOAEL  AUC 0-inf margin to 
female dog  
NOAEL  
     
     
     
     
     
a = observed data and margins based on observed PK parameters  
AUC 0-inf  Extrapolation of the area under the curve from time 0 to infinity; C max  Maximum (peak) plasma drug 
concentration; NOAEL   No-observed -adverse -effect level  
 
3 OBJECTIVES AND ENDPO INTS  
Table  6 Objectives and endpoints  
Objectives  Endpoint/variable:  
Primary objective:   
To assess the safety and tolerability of AZD4041 
following oral administration of single ascending 
doses  • Adverse events  
• Vital signs  
• Hematology, biochemistry, and urinalysis  
• ECG (12 -lead and telemetry)  
• Testosterone, LH, FSH, and inhibin B (male 
subjects only)  
To characteri ze the pharmacokinetics of AZD4041 
following oral administration of single ascending 
doses of AZD4041  • Cmax 
• Tmax 
• AUC 0-t 
• AUC 0-inf 
• t1/2λz 
• CL/F  
• Vss/F 

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  27 of 78  
 Table  6 Objectives and endpoints  
Objectives  Endpoint/variable:  
Secondary objectives:   
Characterize the pharmacodynamic relationship 
between drug exposure and QT interval  An exposure –response (E -R) analysis may be 
conducted with data from this study alone or in combination with other studies as appropriate, with a 
pre-specified workflow described in a separate 
technical document, for the QT interval corrected for 
heart rate using Fridericia’s formula (QTcF) parameter, as part of the cardiac safety evaluation and 
with the intention to obtain a Thorough QT (TQT) study substitute.   The result of the E -R analysis may 
not be included in the main study report.  
AUC 0-t  Area under the curve from time 0 to time t; AUC 0-inf  Extrapolation of the area under the curve from 
time 0 to infinity; CL/F  Apparent total clearance of the drug from plasma after oral administration; 
Cmax  Maximum (peak) plasma drug concentration;  ECG  Electrocardiogram; FSH  Follicle stimulating hormone; 
E-R  Exposure -response; LH  Luteinizing hormone; QTcF  QT interval corrected for heart rate using Fridericia’s 
formula ; t1/2λz  Terminal half-life; Tmax  Time to reach maximum (peak) plasma concentration following drug 
administration; V ss/F  Apparent volume of distribution at steady state after non- intravenous administration  
 
[ADDRESS_1002573] PK in 
humans using PK/ pharmacodynamic ( PD) modelling of data from an in vivo model to identify 
potentially efficacious target concentration  and predicted exposure margins.  
AZD4041 was  predicted to exhibit low clearance and moderate volume of distribution in 
humans.  The human clearance of AZD4041 was  determined via scaling of intrinsic clearance 
data from in vitro human hepatocyte incubations and the application of the well- stirred model 
with appropriate hepatic scaling factors .  The volume of distribution of AZD4041 was 
predicted utilizing in vitro and physicochemical properties and a physiologically- based PK 
model ( PBPK ) (Arundel 1997).  Free efficacious exposure (C eff) in humans was estimated by 
[CONTACT_733744] -induced nicotine- seeking  model in rodents.  
Utiliz ing rat PK and withdrawal model PD data, the maximal efficacious exposure, as 
described by [CONTACT_248977] 90, was  determined using appropriate PK/PD modelling as  free.  
Human dose projections were then  performed using the previously established PBPK model 
and clearance prediction, to estimate the once daily dose required to achieve this target- free 
Ceff at trough plasma concentration  at steady state.  Using this approach, the predicted human 
efficacious . 
The starting dose for the first cohort was  with up to 5 planned dose escalations .  At the 
starting dose of , there was  a predicted  471-fold exposure margin to free C max and 
a 338-fold exposure margin to free AUC 0-inf  when compared to the corresponding 
toxicokinetic parameters for dog NOAEL dose level in male dogs  (Table 7 ).  Dose levels for 
each subsequent cohort were selected based on the emerging safety and PK data; however, the 
predicted exposure was planned  not exceed a limit that is approximately 10 -fold below the 
NOAEL  exposures in the Dog 28- day study  
 
.  Further details regarding data required for dose escalations were provided 
in the SRC Charter  which was  prepared prior to dosing.  For a  single   human dose, the 
corresponding predicted  free C max and free AUC 0-inf exposure margins were expected to  be 13- 
and 10- fold, respectively.  

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  29 of 78  
 Table  7 Bases of predicted human exposure to AZD4041  
Clinical dose  
(mg)  Predicted human 
free C max 
(ng/mL)  Predicted Cmax 
margin to male 
dog NOAEL  Predicted human 
free AUC 0-inf 
(ng·h/mL)  AUC 0-inf margin to 
male dog  
NOAEL  
     
     
     
     
     
     
AUC 0-inf  Extrapolation of the area under the curve from time 0 to infinity; C max  Maximum (peak) plasma drug 
concentration; NOAEL   No-observed -adverse -effect level  
 
Based on the PK exposures observed in Cohorts 1, 2, and 3 ( Table 4 ) the exposure limits , 
based on the male dog NOAEL, we re expected to be reached in the 4th cohort.  
Therefore, the protocol wa s amended to only enroll female subjects of non- childbearing 
potential and vasectomised male subjects in the study in all subsequent cohorts. 
The initial exposure limits set in the study were  based on testicular toxicity seen in the 28- day 
dog GLP toxicity study.  For the purpose of a single dose study, testicular toxicity is not 
considered to be relevant for vasectomised male or female subjects of non -childbearing 
potential.  It is therefore considered appropriate to enroll vasectomised males or female subjects of non-childbearing potential only in cohorts where exposures are predicted to exceed 
the 10-fold margin below the Dog 28-day study NOAEL exposures, ie, Cohort 4 onwards. 
In the 28-day GLP toxicity study, adverse effects in the form of increased incidence and 
severity of thymic atrophy characterised by [CONTACT_733745], were noted at the high dose in female dogs.  A similar increase in incidence and severity was not noted in the male dog.  As a result, the NOAEL was set  at the intermediate 
dose. Therefore, for cohorts where exposures are predicted to exceed the 10 -fold margin 
below the Dog 28- day study NOAEL  (Cohort 4 onwards) , revised exposure limits are 
proposed not to exceed a free C
max of  
 w hich correspond 
to the intermediate dose NOAEL exposures in the female dog at .  Revised 
exposure margins for female and vasectomized male subjects are provided in Table 5. 
 

Clinical Study Protocol Amendment [ADDRESS_1002574] expected visit/contact [CONTACT_733746]. 
A subject  is considered to have completed the study when the subject  has completed his/her 
last scheduled visit or last scheduled procedure, shown in the SoA ( Table 1 and Table 2) . 
See Appendix A [ADDRESS_1002575] should meet all of the inclusion criteria and none of the exclusion criteria for this 
study in order to be assigned/randomized to a study intervention.  Under no circumstances can 
there be exceptions to this rule.  Subjects who do not meet the entry requirements are screen 
failures (refer to Section 5.4). 
In this CSP , “enrol led” subjects are defined as those who sign informed consent.  
“Randomized” subjects are defined as those who undergo randomization and are assigned  a 
randomization number. 
For procedures for withdrawal of incorrectly enrolled subjec ts, see Section 7.3. 
5.1 Inclusion criteria  
Subjects are eligible to be included in the study only if all of the following inclusion criteria 
and none of the exclusion criteria apply: 
1 Capable of giving signed informed consent, which includes compliance with the 
requirements and restrictions listed in the  Informed Consent Form ( ICF) and in this CSP . 
[ADDRESS_1002576] be ≥18 and ≤55 years of age at the time of signing the ICF. 
4 Individuals who are healthy as determined by [CONTACT_74560] , including medical 
history, physical examination, laboratory tests, and cardiac monitoring. 
5 Individuals who weigh ≥[ADDRESS_1002577] a body mass index (BMI) between 18.0 and 30.0 kg/m
2, inclusive. 
[ADDRESS_1002578] be of non-childbearing potential, as confirmed at screening by 
[CONTACT_733747] c riteria:  
(a) Post-menopausal women must have had ≥12 months of spontaneous amenorrhea with 
a follicle stimulating hormone  (FSH) concentration consistently ≥40 mIU/mL and 
must have a negative pregnancy test result at  screening and check-in. 
(b) Surgically sterile women , defined as those who have had a hysterectomy, bilateral 
ovariectomy (oophorectomy), bilateral salpi[INVESTIGATOR_1656],  or bilateral tubal ligation.  
Women who are surgically sterile must provide documentation of the procedure by 
[CONTACT_733748], or by [CONTACT_2207], and must have a 
negative pregnancy test result at screening and check -in. 
[ADDRESS_1002579]’s ability to participate in the s tudy.  
2 History of any significant psychiatric disorder according to the criteria of the Diagnostic 
and Statistical Manual of Mental Disorders, 5
th Edition ( American Psychiatric Association 
2013) which, in the opi[INVESTIGATOR_689], could be detrimental to subject safety or 
could compromise study data interpretation. 
3 Male subjects with a history of oligospermia or azoospermia or any other disorder of the reproductive s ystem . 
4 Subjects who are undergoing treatment or evaluation for infertility. 
5 History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs. 
6 Any cli nically important illness, medical/surgical procedure or trauma within [ADDRESS_1002580], defined as any of the following: 
(a) Systolic BP <90 mmHg or ≥140 mmHg . 
(b) Diastolic BP <50 mmHg or ≥90 mmHg . 
(c) HR <45 or >85 beats per minute. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  32 of 78  
 10 Any clinically important abnormalities in rhythm,  conduction, or morphology of the 
resting ECG and  any clinically important abnormalities in the 12 -lead ECG which, in the 
Investigator’s opi[INVESTIGATOR_1649], may interfere with the interpretation of QTc  interval changes, 
including abnormal ST-T- wave morphology. 
[ADDRESS_1002581] ( QT) 
interval corrected for HR using Fridericia’s formula  (QTcF ) >[ADDRESS_1002582] to the onset of the QRS complex 
(PR[PQ]) interval shortening <120 ms (PR >110 ms but <120 ms is acceptable if there is 
no evidence of ventricular pre- excitation) . 
13 PR(PQ) interval prolongation (>240 ms) , persistent or intermittent second (Wenckebach 
block while asleep is not exclusive) or third degree atrioventricular  (AV) block, or AV 
dissociation . 
14 Persistent or intermittent complete bundle branch  block (BBB), incomplete bundle branch 
block (IBBB), or intraventricular conduction delay (IVCD) with ECG interval measured 
from the onset of the QRS  complex to the J point (QRS) >110 ms.  Subjects with QRS  
>110 ms but <115 ms are acceptable if there is no  evidence of , eg, ventricular 
hypertrophy or pre- excitation . 
15 In the pre-dose 24 hour telemetry, presence of ≥10 ventricular premature contractions (VPCs) during 1 hour, or ≥100 VPCs during 24 hours of Holter/telemetry or any 
occurrence of paired VPCs (ventricular couplets) or other repetitive ventricular rhythms including non-sustained or sustained (>30 second duration) “slow” (<100 bpm) or “fast” 
(≥100 bpm) ventricular tachycardias. 
[ADDRESS_1002583] smoked or used nicotine products within the previous 3 months. 
19 History of alcohol abuse or excessive intake of alcohol defined as an average weekly 
intake of >21 units or an average daily intake of >3 units for men or an average weekly 
intake of >14 units or an  average daily intake of >2 units for women.  One  unit is 
equivalent to a half pi[INVESTIGATOR_11731] (250 mL) of beer, 1  measure (2 5 mL) of spi[INVESTIGATOR_2120], or 1 glass 
(125 mL) of  wine.  If a subject is currently diagnosed with abuse of or dependence on 
alcohol, the subject  will not be allowed to enroll in the study, unless the alcohol 
abuse/dependence is in full (complete, not partial), sust ained (>1 year) remission.  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  33 of 78  
 20 Positive screen for drugs of abuse at screening or admission to the unit or positive screen 
for alcohol at screening  to the unit prior to administration of IP. 
21 History of severe allergy/hypersensitivity or  ongoing clinically impo rtant 
allergy/hypersensitivity, as judged by [CONTACT_16032], or history of hypersensitivity to 
drugs with a similar chemical structure or class to  AZD4041. 
22 Plasma donation within 1 month of screening or any blood donation/blood loss >500 mL 
during the 3 months prior to screening. 
23 Excessive intake of caffeine -containing drinks or food (eg, coffee, tea, chocolate) as 
judged by [CONTACT_737]. 
[ADDRESS_1002584] John’s w ort, within 3 weeks 
prior to administration of IP. 
25 Use of any prescribed or nonprescribed medication including antacids, analgesics (other 
than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to 
administration of IP or longer if the medication has a long half- life. 
26 Use of any prescribed or nonprescribed oral and topi[INVESTIGATOR_113042]/inducers of CYP3A4 
(including shampoo). 
[ADDRESS_1002585] previously received AZD4041. 
29 Has received another new chemical entity (defined as a compound that has not been 
approved for marketing) within [ADDRESS_1002586].  Note: subjects consented and screened, but not randomized in this study or 
a previous Phase I study, are not excluded. 
[ADDRESS_1002587] any ongoing or recent (ie, during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements. 
[ADDRESS_1002588] meals and snacks at regimented times during each residential 
period. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  34 of 78  
 Subjects should not consume grapefruit juice or other grapefruit products for up to 7 days 
before dosing and throughout the study. 
 Caffeine, alcohol, and tobacco 
Alcohol use is prohibited for 48 hours prior to the screening visit, for 48 hours  prior to 
admission to the unit, during the residential period, and for 48 hours prior to the follow-up 
visit ([ADDRESS_1002589]-dose) .  Subjects should consume only moderate levels of alcohol for the 
duration of the study, defined as less than 3 units (1 unit=25 mL spi[INVESTIGATOR_2120], 125 mL wine or 
250 mL beer or lager) in any 24-hour period for men and less than 2 units in any 24-hour 
period for women. 
 Activity 
Strenuous activity is prohibited from 48 hours prior to admission to the Clinical Research Unit (CRU) until discharge from the CRU. 
5.4 Screen failures  
Screen failures are defined as subjects who signed the ICF to participate in the clinical study 
but are not subsequently randomiz ed.  A minimal set of screen failure information is required 
to ensure transparent reporting of screen failure subjects to meet  the Consolidated Standards 
of Reporting Trials (CONSORT) publishing requirements and to respond to queries from 
regulatory authorities .  Minimal information includes demography, screen failure details, 
eligibility criteria, and any serious adverse event ( SAE).  
Individuals who do not meet the criteria for participation in this study (screen failure) may not 
be rescreened.  
These subjects should have the reason for study withdrawal recorded in the electronic Case 
Report Form (e CRF ). 
6 STUDY TREATMENTS  
Study tre atment is defined as any  IP (including marketed product comparator and placebo) or 
medical device(s) intended to be administered to a study participant according to the CSP . 
Study treatment is to be administered in the morning under fasted conditions.  Subjects will 
fast overnight (nothing to eat or drink except water) for at least 10 hours before receiving study treatment.  Subjects will remain fasted for 4  hours after dosing with study treatment.  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  35 of 78  
 6.1 Treatments administered  
 Investigational products 
Table  8 Study treatments  
Study treatment name:  [CONTACT_99213]4041  
Dosage formulation:   
 
Strength/Concentrations:   
Placebo :  
 
Route of administration :  Oral 
Dosing instructions:  Oral syringe  
Packaging and labelling:  Formulation to be prepared extemporaneously from drug substance at the 
clinical site.  Stock solutions to be prepared on a weekly basis and stored 
under refrigerated conditions (2 °C to 8 °C).  Dosing solutions to be prepared 
on a daily basis for use within 24 hours and may be stored under ambient 
conditions.  
Provider : AMRI, Albany, Ne w York  
 
6.2 Preparation/handling/storage/accountability  
The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment received and any discrepancies are reported 
and resolved before us e of the study treatment.  
Only subjects enrolled in the study may receive study treatment and only authoriz ed site staff 
may supply or administer study treatment.  All study treatments must be stored in a secure, 
environmentally controlled and monitored (manual or automated) area, in accordance with the labelled storage conditions, with access limited to the Investigator and authoriz ed site staff.  
Details of study treatment preparation and administration are given in the Handling 
Instructions. 
A formal sy stem for drug accountability will be implemented .  The Investigator, institution, or 
the head of the medical institution (where applicable) is responsible for study treatment 
accountability, reconciliation, and record maintenance (ie, receipt, reconciliati on, and final 
disposition records). 

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  36 of 78  
 6.3 Measures to minimize bias: randomization and blinding  
[COMPANY_003] will generate the randomization schedule.  Eligible sentinel subjects within each cohort 
will be randomly assigned in a ratio of 1:1 to Active:Placebo after all e ntry criteria have been 
satisfied before dosing on Day 1.  Follow ing review of sentinel safety data up to [ADDRESS_1002590]-dose, the remaining subjects within each cohort will be randomly assigned in a ratio of 
5:1 to Active:Placebo. 
 Blinding Procedures 
This is a double-blind study.  Neither the subjects nor the investigator will be aware of the treatment assignment.  Blinding will be maintained throughout the study by [CONTACT_733749].  Access to the randomizat ion code will be strictly 
controlled according to the standard operating procedures of [COMPANY_003]. 
 Breaking the Blind 
Blind breaking envelopes will be prepared.  A subject or subjects may be unblinded in the event of a dose- limiting toxicity, SAE, or other event,  or if there is a medical emergency 
where the identity of the drug must be known to properly treat a subject.  A cohort may be unblinded to determine if dose escalation to the next dose level will terminate.  If a subject 
becomes seriously ill or pregnant during the study, the blind will be broken only if knowledge of the administered study drug will affect that subject’s treatment options.  In the event of a 
medical emergency requiring identification of the study drug administered to an individual subject,  the investigator will make every attempt to contact [CONTACT_733750] 24 hours of opening the code.  The investigator will be responsible for documenting the time, date, reason for the code break, and the names of the personnel involved. 
6.4 Treatment compliance  
Any change from the dosing schedule, dose interruptions, dose reductions, or dose discontinuations should be recorded in the eCRF. 
The Investigator is responsible for management of the IP from receipt b y the study site until 
the destruction or return of all unused IP.  
6.5 Concomitant therapy  
Any medication or vaccine including over-the-counter or prescription medicines, vitamins, 
and/or herbal supplements that the subject  is receiving at the time of enrollment  or receives 
during the study must be recorded along with: 
• Reason for use 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  37 of 78  
 • Dates of administration , including start and end dates 
• Dosage information, including dose and frequency 
 
Table 9 Restricted medications  
Medication/class of  drug:  Usage (including limits for duration permitted and 
special situations in which it is allowed): 
Antacids  
Analgesics other than paracetamol/acetaminophen  
Herbal remedies  
Megadose (20 to 600 times recommended daily 
dose) vitamins  
Megadose minerals  In the [ADDRESS_1002591]  
 
Table 10 Prohibited medications  
Prohibited medication/class of drug:  
Any other investigational drugs than provided in this study  
Any medication with enzyme inducing properties such as St John’s wort 
Hormone replacement therapy  
Oral and topi[INVESTIGATOR_113042]/inducers of CYP3A4  
Vaccination with COVID -[ADDRESS_1002592] ’s 
safety and wellbeing, may be given at the discretion of the Investigator and recorded in the 
appropriate section of the eCRF . 
[ADDRESS_1002593]  
WITHDRAWAL  
7.1 Discontinuation of study treatment  
As individual subjects are given only one dose of IP, there are no criteria for discontinuing study treatment.  This section describes the criteria for study termination and the 
discontinuation of planned dos e escalation s within the study.  
The sponsor designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the sponsor. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  38 of 78  
 The study may be stopped if, in the judg ement  of [COMPANY_008], trial subjects are placed at 
undue risk because of clinically significant findings that: 
• Meet individual stoppi[INVESTIGATOR_103414] 
• Are assessed as causally related to IP 
• Are not considered to be consistent with continuation of the study 
 
Regardless of the reason for termination, all data available for the subject at the time of 
discontinuation of follow-up must be recorded in the CRF. 
In terminating the study, the sponsor will ensure that adequate consideration is given to the 
protection of the subjects’ wellbeing . 
After each cohort , an SRC will review and assess all the available safety and PK data from all 
of the cohorts to date in order to make a decision on the dose for the next cohort of subjects. 
Data from a minimum of  [ADDRESS_1002594] be reviewed before each dose 
escalation.  
If any of the following scenarios occur within a cohort with a reasonable possibility of a 
causal relationship with AZD4041, escalation to the next, higher dosage level may not occur: 
General  
• One or more subjects, who receive AZD4041, report a SAE  or experience AEs judged to 
be non- tolerable by [CONTACT_978] [INVESTIGATOR_733733], and are deemed related to AZD4041.  
 
Cardiovascular c riteria  
• Two or more subjects, who receive AZD4041, have QTc prolongation defined as QTcF 
>500 ms, or a prolongation from baseline of >60 ms, confirmed (persistent for at least 
5 min utes) and determined post-dose either during continuous 12-lead ECG monitoring or 
on a repeat 12- lead ECG.  
• Two or mor e subjects , who receive AZD4041, have tachycardia defined as resting supi[INVESTIGATOR_718101] >[ADDRESS_1002595] 10 minutes.  
• Two or more subjects, who receive AZD4041, have symptomatic bradycardia defined as 
resting supi[INVESTIGATOR_113045] <40 beats per minute or asymptomatic bradycardia defined as resting 
supi[INVESTIGATOR_113045]  <[ADDRESS_1002596] 10  minutes.  
• Two or more subjects, who receive AZD4041, develop hypertension defined as an 
increase in resting supi[INVESTIGATOR_733734] >[ADDRESS_1002597] 10  minutes.  
• Two or more subjects, who receiv e AZD4041, develop hypotension defined as an 
asymptomatic fall in systolic  BP of >20 mmHg to <[ADDRESS_1002598] 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  39 of 78  
 10 minutes, or a sympt omatic fall in resting supi[INVESTIGATOR_30991] >20  mmHg (excluding vasovagal 
reaction).  
• Two or more subjects, who receive AZD4041, have tachycardia defined as resting supi[INVESTIGATOR_733735] >[ADDRESS_1002599] 10 minutes.  
• Two or more subjects, who receive AZD4041, have a non-sustained ≥5 beat if “slow” 
(<100 bpm), or “fast”(≥100 bpm) ventricular tachycardia. 
• One or more subjects, who receive AZD4041, have a sustained ventricular tachycardia 
(ie, >30 second duration, or leading to hemodynamic consequences requiring immediate 
arrhythmia termination) . 
Laboratory f indings  
• One or more subjects, who receive AZD4041, fulfill Hy’s Law defined as “An increase in 
aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3x upper l imit of 
normal (U LN) and t otal bilirubin (TBL) ≥2x ULN, where no other reason can be found to 
explain the combination of increases; eg, elevated serum alkaline phosphatase (ALP) 
indicating cholestasis, viral hepatitis,  or another drug.”  The elevations do not have to be 
at the same time or within a specified time frame.  
• Two or more subjects, who receive AZD4041, have >3x ULN of either ALT or AST, or 
>2x ULN for  TBL  or ALP.  
 
Criteria for halting dose escalation 
PK data indicate that the p redefined maximum exposure level/maximum plasma concentration 
(free C max of  
h as been achieved, or is predicted to be achieved or 
exceeded should the dose be increased as planned.  The exposure limits should be applied on 
mean values within a cohort.  If this halting dose escalation criterion is met, the SRC will stop 
any further  dose escalation .  The SRC will determine whether a lower or the same dose should 
be tested or whether the study should be terminated. 
7.[ADDRESS_1002600] fails to return to the clinic for a required 
study visit: 
• The site must attempt to contact [CONTACT_733751].  
• Before a subject  is deemed lost to follow-up, the Investigator or designee must make 
every effort to regain contact [CONTACT_733752] , eg, repeat telephone calls, 

Clinical Study Protocol Amendment [ADDRESS_1002601] ´s last known mailing address or local equivalent methods.  
These contact [CONTACT_9300]’s medical record.  
• Efforts to reach the subject should continue until the end of the study.  Should the subject  
be unreachable at the end of the study, the subject should be considered to be lost to 
follow-up with unknown vital status at end of study and censored at latest follow-up 
contact.  
 
7.[ADDRESS_1002602]  may with draw from the study (eg, withdraw consent), at any time ( IP and 
assessments) at the subject’s own request.  There will be no penalty or loss of benefit to the 
subject.  
A subject  who considers withdrawing from the study must be informed by [CONTACT_230592]-up options (eg, telephone contact, a contact [CONTACT_4490] a relative or treating 
physician, or information from medical records).  Circumstances of withdrawal will be 
documented in writing by [CONTACT_737]. 
If the subject  withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  
If a subject  withdraws from the study, the subject  may request destruction of any samples 
taken, and the Investigator must document this in the site study records.   
A subject  who withdraws consent will always be asked about the reason(s) and the presence of 
any AE .  The Investigator will follow up with subjects as medically indicated .  
See SoA ( Table 1 and Table  2), for data to be collected at the time of study discontinuation 
and follow-up and for any further evaluations that need to be completed.   
8 STUDY ASSESSMENTS AND PROCEDURES  
Study procedures and their timing are summarized in the SoA ( Table 1 and Table 2). 
The Investigator ensures the accuracy  and completeness of eCRFs , including  eligibility  and 
timeliness of the data recorded and of the provision of answers to data queries according to the 
Data Management Plan.   The Investigator will sign the completed eCRFs .  A copy of the 
completed eCRFs  will be archived at the study site.  
Immediate safety concerns should be discussed with the sponsor immediately upon occurrence or awareness to determine if the subject  should continue or discontinue s tudy treatment.  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  41 of 78  
 Adherence to the study design requirements, including those specified in the SoA ( Table 1 and 
Table 2), is essential and required for study conduct. 
All screening evaluations must be completed and reviewed to confirm that potential subject s 
meet all eligibility criteria .  The Investigator will maintain a screening log to record details of 
all subjects screened and to confirm eligibility or record reasons for screening failure, as 
applicable.   
Procedures conducted as part of the subject’s routine clinical management (eg, blood count) 
and obtained before signing of the ICF may be utilized for screening or baseline purposes 
provided the procedures met the CSP -specified criteria and were performed within the time 
frame defined in the SoA.  
The maximum amount of blood collected from each subject  over the duration of the study, 
including any extra assessments that may be required, will not exceed 150 mL.  Repeat or 
unscheduled samples may be taken for safety reasons or for technical issues wit h the samples.  
8.1 Efficacy assessments (not applicable)  
8.2 Safety assessments  
Planned time points for all safety assessments are provided in the SoA ( Table 1 and Table 2 ). 
 Clinical safety laboratory assessments 
The clinical chemistry, hematology , and urinalysis will be performed at a local laboratory at 
or near to the study site. 
See Table [ADDRESS_1002603] of clinical safety laboratory tests to be performed and to the SoA  
(Table 1 and Table 2) for the timing and frequency .  All CSP-required laboratory assessments, 
as defined in the table, must be conducted in accordance with the laboratory manual and the 
SoA ( Table 1 and Table 2).  
The Investigator should make an assessment of the available results with regard to clinically relevant abnormalities .  The laboratory results should be signed, dated , and retained at center  
as source data for laboratory variables.  
For information on how AEs based on laboratory tests should be recorded and reported, see Section 8.3.7. 
Additional safety samples may be collected  and analyz ed if clinically indicated at the 
discretion of the Investigator.  The date of collection  will be recorded on the appropriate CRF. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  42 of 78  
 Table 11 Laboratory safety variables  
Hematology  (whole blo od) Clinical Chemistry (serum or plasma)  
White blood cell (WBC) count  Alanine aminotransferase  (ALT)  
Red blood cell (RBC) count  Aspartate aminotransferase (AST)  
Hemoglobin  (Hb)  Alkaline phosphatase (ALP)  
Hematocrit (HCT)  Gamma glutamyl transpeptidase (GGT)  
Mean corpuscular volume (MCV)  Total bilirubin  
Mean corpuscular hemoglobin (MCH)  Unconjugated bilirubin  
Mean corpuscular hemoglobin concentration (MCHC)  C-reactive protein (CRP)  
Neutrophils absolute count  Blood Urea Nitrogen 
Monocytes absolute count  Creatinine  
Eosinophils absolute count  Glucose (fasting)  
Basophils absolute count  Albumin  
Platelets  Phosphate  
Reticulocytes absolute count  Potassium  
 Calcium  
Urinalysis  Sodium  
Glucose  Bicarbonate 
Protein  Thyroid stimulating hormone (TSH )a 
Hemoglobin Thyroxine (T 4)b 
Microscopy (if positive for blood or protein)  Follicle stimulating hormone (FSH)c 
Viral serology  Pregnancy test (females only)  
Human immunodeficiency virus (HIV I and II)  Human beta chorionic gonadotrophin  
Hepatitis B surface  antigen (HBsAg)   
Hepatitis C Virus antibody   
a Screening only 
b Reflex only (if TSH is abnormal)  
c Screening for post -menopausal  women  
NB.  In case a subject  shows an AST or ALT ≥3xULN together  with total bilirubin  ≥2xULN refer to Appendix  C 
‘Actions required in cases of increases in liver biochemistry and evaluation of Hy’s Law’, for further instructions  
 
Urine will be tested for  alcohol and cotinine (screening only) and the following drugs of 
abuse:  amphetamines (includes methamphetamines and 
ecstasy/ 3,4-methylenedioxymetamphetamine ), barbiturates, benzodiazepi[INVESTIGATOR_1651], cannabinoids 
(includes tetrahydrocanabinol), cocaine metabolites, methadone, tricyclic antidepres sants, 
opi[INVESTIGATOR_858] (includes heroin, codeine, and oxycodone), and phencyclidine. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  43 of 78  
 
 Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone, and 
inhibin B assessments 
In order to monitor for effects on testicular function in male subje cts, samples for assessment 
of testosterone, luteinizing hormone ( LH), FSH , and i nhibin B levels will be collected at 
0 hour (0800 or 1000) and at 4, 6, 8, 12, 22, and 24 hours on Day - 1 and at 0 hour (0800 or 
1000) and at 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 hours on Day 1, as listed in the SoA ( Table 2).  
The results of these assessments will be taken into account at dose escalation meetings, prior 
to selecting the dose for the next cohort. 
 Physical examinations 
A complete physical examinat ion will be performed and include an assessment of the 
following systems: cardiovascular, chest/lungs/respi[INVESTIGATOR_696], gastrointestinal, thyroid/neck, 
lymphatics, dermatological/skin, musculoskeletal/extremities, neurological, and head/ears/eyes/nose/throat (i ncluding mouth). 
Physical examination will be performed at timelines as specified in the SoA.  Investigators 
should pay special attention to clinical signs related to previous serious illnesses ; new or 
worsening abnormalities may qualify as AEs; see Section 8.3.7 for details.  
 Vital signs 
Body  temperature, pulse rate (PR), respi[INVESTIGATOR_697] , and BP  will be assessed.  
Vital signs will be measured in a semi-supi[INVESTIGATOR_55848] [ADDRESS_1002604] 1  minute .  The average of the 3 BP 
readings will be recorded on the CRF.  
Respi[INVESTIGATOR_733736] ( Table 1 and Table 2). 
 Electrocardiograms 
For the timing of ECG assessments, see the SoA ( Table 1 and Table 2) and Table 12. 
Twelve- lead paper ECG (pECG) allows the PI [INVESTIGATOR_733737] .  Digital 12 -lead ECGs are collected and electronically submitted 
to the Astr aZeneca ECG Center  for expert review and reporting of ECG intervals.  Telemetry 
is used for continuous monitoring of ECG activity as a safety measure. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  44 of 78  
 [IP_ADDRESS] Resting 12- lead ECG  
Twelve-lead pECGs will be obtained after the subject has been resting in the supi[INVESTIGATOR_49844] 10  minutes .  All pECGs will be evaluated for  HR,  and for PR, RR, QRS, QT, and 
QTcF intervals, and the Investigator will judge the overall interpretation as normal or 
abnormal.  If abnormal, it will be decided whether or not the abnorma lity is clinically 
significant or not clinically significant, and the reason for the abnormality will be recorded.  The date/time, physician interpretation (normal, abnormal clinically significant, abnormal not 
clinically significant), and all evaluated parameters and intervals will be recorded in the eCRF, 
and the paper printouts will be stored at the site. 
The PI [INVESTIGATOR_733738], and with particular 
attention to the effects of clinical importance on the  PR, QRS , and QTcF intervals.  
[IP_ADDRESS] Electronic capture and analysis of 12 -lead digital ECGs  
The [COMPANY_008] ECG Center  will perform the digital ECG ( dECG ) analysis and 
interpretation in this  study, using the EClysis
© system, version 4.0, or higher. 
Continuous 12- lead dECG recordings will be performed using the site’ s Mortara Telemetry 
Surveyor equipment.  At CSP -indicated time points in Table 12, 12-lead continuous dEC G 
files will be extracted over at least 5  minutes from the Mortara Telemetry Surveyor 
continuous files and transmitted to the [COMPANY_008] central dECG repository, according to [COMPANY_008] ECG Center ’s standard procedures, settings, recording, and transmission of 
dECGs.  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  45 of 78  
 Table 12 SAD single dose time schedule for digital electrocardiogram  assessments 
in D7460C00001 during the residential period 
Study 
Days  ECG  
Number  Time -
point  Start Time  
hour:mina,b Dose  Stop 
Time  dECG cont.c,d,e Otherf 
1   -01:30  -01:00  Apply the 
electrodesd 
1   -00:40  -00:[ADDRESS_1002605] in bed  
1 1 Pre-dose -00:30 Predose  -00:20 10 minutes   
1   -00:20  -00:05  Toilet use 
recommended  
1   00:00 IP Admin     
1 2 30 min 00:25  00:30 5 minutese  
1 3 1 h 00:55  01:00 5 minutese  
1 4 1.5 h  01:25  01:30 5 minutese  
1 5 2 h 01:55  02:00 5 minutese  
1 6 3 h 02:55  03:00 5 minutese  
1 7 4 h 03:55  04:00 5 minutese  
1 8 6 h 05:55  06:00 5 minutese  
1 9 8 h 07:55  08:00 5 minutese  
1 10 12 h 11:55   12:00  5 minutese  
2 11 24 h 23:55   24:00  5 minutese  
2 12 36 h 35:55   36:00  5 minutese  
3 13 48 h 47:55   48:00  5 minutese  
4 14 72 h 71:55   72:[ADDRESS_1002606] be in the same supi[INVESTIGATOR_113050] (max. 30 degrees flexion in the hip) at each time point 
and at all visits.  Subject’s feet should not contact [CONTACT_718147] . 
d Skin must be cleaned, and electrode positions marked with an indelible pen. Electrodes should be applied at 
least [ADDRESS_1002607] 10  minutes prior to each ECG time point. 
f On the dosing days, safety ECG will be printed at t he end of each  dECG extraction window . 
dECG   Digital electrocardiogram; ECG   Electrocardiogram; IP  Investigational product; PK   Pharmacokinetics ; 
SAD  Single ascending dose  
 
The same recording device will be used for each subject at all time points, when possible.  
Date and time settings must be checked on the Mortara Telemetry Surveyor at the start of each 
study day and aligned with an official timekeeper.  
Skin preparation must be thorough and electrode positions must be according to standard 12-lead ECG placement.  
Clinical Study Protocol Amendment [ADDRESS_1002608] 10  minutes (can be reduced to [ADDRESS_1002609] hour after dosing) before the start of each recording.  
The subject should be in the same supi[INVESTIGATOR_113050] (maximum [ADDRESS_1002610]) at each recording time point during the study. 
The metadata for all dECG files will be checked by [CONTACT_733753] .  As a standard, 10- second ECGs will be extracted by [CONTACT_113108]
© system twice per 
minute from the continuous recording and initially automatically analyzed by [CONTACT_19915]. 
Lead V2 will be analyzed and reported as primary .  Lead V5 will be analyzed, for all visits, as 
backup for the individual where analysis in lead V2 is not deemed possible for pre -dose, for 
significant parts of visits or for whole visits.  
The ECG Scientific Advisor will perform all required manual corrections to the ECG annotations provided automatically by [CONTACT_113109]
©. 
To provide a decision basis for dose escalation, the EC G Scientific Advisor(s) will perform a 
preliminary analysis of the first [ADDRESS_1002611] will review the totality of the data and perform all necessary 
adjustments before locking the EClysis
© data into a read -only s tate, before the data will be 
exported. 
The numerical values for ECG intervals and amplitudes will be exported and made accessible 
on the [COMPANY_008] dECG Central repository to accredited data management specialists for 
conversion into SAS® files.  
The foll owing dECG variables will be reported by [CONTACT_718160] : RR, PR, 
QRS and QT intervals from the lead defined as the primary analyses lead .  Derived parameters 
(QTcF, HR, and others, as applicable) are calculated by [CONTACT_733754].  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  47 of 78  
 [IP_ADDRESS] Telemetry (real -time display) 
To allow a real -time assessment of cardiac safety at the study site, subjects will be monitored 
by [CONTACT_63199] (for real -time assessment of cardiac rate and rhythm)  for [ADDRESS_1002612]-dose. Subjects with NSVT and excessive VPCs will be excluded 
from pre -dose telemetry.  Any clinically significant change noted on telemetry will be 
followed up with a 12- lead ECG .  Fur ther evaluation and treatment will be performed as 
deemed appropriate by [CONTACT_737] .  Any finding of short, self- limiting, asymptomatic 
arrhythmia (eg, non- significant tachycardia, atrial fibrillation or flutter) that does not require 
any medical intervention , should be documented and further evaluated in the context of the 
individual subject’s history and clinical status .  Irrespective of the intervention, cardiac 
monitoring will be continued until the event resolves or the subject is deemed clinical ly stable 
by [CONTACT_737]. 
8.[ADDRESS_1002613].   
The Investigator and any designees are responsible for detecting, documenting, and recording 
events that meet the definition of an AE or SAE.  For information on how to follow-up AEs, 
see Section 8.3.3. 
 Method of detecting AEs and SAEs 
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and 
non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrences.   
 Time period and frequency for collecting AE and SAE information  
Serious AE s will be collected from  the time of signature [CONTACT_357925], throughout the treatment 
period, and including the follow-up period and last contact.  Adverse events will be collected from the time of administration  of IP.  Non -SAEs  occurring between the time of signature [CONTACT_733766].  
All SAEs will be recorded and reported to the sponsor or designee within [ADDRESS_1002614] ’s 
last visit and the Investigator  considers the event to be reasonably related to the study 
treatment or study participation, the Investigator may notify the sponsor. 
The method of recording, evaluating, and assessing causality of AE and SAE and the 
procedures for completing and transmitting SAE reports are provided in Section 8.4.1 and  
Appendix B . 
 Follow-up of AEs and SAEs 
After the initial AE/SAE report, the Investigator is required to proactively follow each subject  
at subsequent visits/contacts.  A ll AEs will be followed until resolution, stabiliz ation , the 
event is otherwise explained, or the subject  is lost to follow -up  
Any AEs that are unresolved at the subject ’s last AE assessment in the study are followed up 
by [CONTACT_96770], but without further recording in the CRF .  [COMPANY_008] retains the right to request additional information for any subject  with 
ongoing AE(s)/SAE(s) at the end of the study, if judged necessary. 
 Adverse event data collection 
The following variables will be collected for each AE : 
• AE (verbatim)  
• The date and time when the AE started and stopped 
• Intensity of the AE 
• Whether the AE is serious or not 
• Investigator causality rating against the IP (yes or no) 
• Action taken with regard to IP 
• Whether the AE caused  the subject’s withdrawal from study (yes or no ) 
• Outcome of the AE 
 
In addition, the following variables will be collected for SAEs: 
• Date AE met criteria for SAE 
• Date Investigator became aware of SAE 
• AE is serious due to 
• Date of hospi[INVESTIGATOR_1838]  
• Date of discharge  
• Probable cause of death  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  49 of 78  
 • Date of death  
• Autopsy performed 
• Causality assessment in relation to study procedure(s) 
• Causality assessment to other medication  
• Description of the S AE 
 
 Causality collection 
The Investigator  will assess causal relationship between IP and each AE, and  answer ‘yes’ or 
‘no’ to the question ‘Do you consider that there is a reasonable possibility that the event may 
have been caused by [CONTACT_33249]?’ 
For SAEs, causal relationship will also be assessed for other concomitant medication and 
study procedures.  Note that for SAEs that could be associated with any study procedure, the causal relationship is implied as ‘yes’.  
A guide to the interpretation of the causality question can be found in Appendix B . 
 Adverse events based on signs and symptoms 
All AEs spontaneously reported by [CONTACT_733755]: ‘Have you had any health problems since you were last asked ?’ or 
revealed by [CONTACT_4171] , will be collected and recorded in the CRF.  When collecting AEs, the 
recording of diagnoses is preferred (when possible) to recording a list of signs and symptoms.  However, if a diagnosis is known and there are other signs or symptoms that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately. 
 Adverse events based on examinations and tests 
The results from the CSP -mandated laboratory tests and vital signs will be summarized in the 
Clinical Study Report (CSR) .  Deterioration as compared to baseline in CSP-mandated 
laboratory values or vital signs should therefore only be reported as AEs if they fulfill any of 
the SAE criteria , are the reason for discontinuation of treatment with the IP, or qualify as AEs 
of interest . 
If deterioration in a laboratory value/vital sign is associated with clinical sign s and symptoms, 
the sign or symptom will be reported as an AE and the associated laboratory result/vital sign will be considered as additional information .  Wherever possible, the reporting Investigator 
uses the clinical, rather than the laboratory term (eg, anemia versus low h emoglobin value) .  
In the absence of clinical signs or symptoms, clinically relevant deteriorations in non-
mandated parameters should be reported as AE(s).  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  50 of 78  
 
 Hy’s Law  
Cases where a subject shows elevations in liver biochemistry may require further evaluation 
and occurrences of AST or ALT ≥3x ULN together with TBL  ≥2x ULN may need to be 
reported as SAEs .  Refer to  Appendix C  for further instruction on cases of increases in liver 
biochemistry and evaluation of Hy’s Law (HL).  
8.[ADDRESS_1002615] to be reported, whether or not considered causally related to the IP or to the 
study procedure(s).  All SAEs will be recorded in the CRF.  
If any SAE occurs in the course of the study, Investigators or other site personnel will inform 
the Medical Monitor; the [COMPANY_008] study physician or physician designate ; and MMS 
Holdings, Inc immediately, or no later than 24 hours after they become aware of the SAE (initial report) using the SAE Rep ort Form provided by [CONTACT_733756].  Telephone and email 
reports must be confirmed promptly either by [CONTACT_226114]. 
For fatal or life -threatening AEs where important or relevant information is missing, active 
follow-up is undert aken immediately .  The Investigator or other site personnel will inform the 
Medical Monitor; the [COMPANY_008] study physician or physician designate; and MMS 
Holdings, Inc of any follow-up information on a previously reported SAE immediately, or no later th an [ADDRESS_1002616] information for the [COMPANY_008] study physician, the Medical Monitor, and MMS 
Holdings, Inc are included in the Study Manual. 
For guidance on the definition of an SAE, see Appendix B . 
 Pregnancy 
All pregnancies and their subsequent outcome (spontaneous miscarriage, elective termination, 
ectopic pregnancy, normal birth, or congenital abnormality) should be reported to: 
 
 
 
 
The reports should be made using the  Pregnancy Notification and Outcome Form. 
[IP_ADDRESS] Maternal exposure  
Women of childbearing potential are not allowed to be included in this study.   

Clinical Study Protocol Amendment [ADDRESS_1002617] interfered with the effectiveness of a contraceptive medication .  Congenital 
abnormalities/birth defects and spontaneous miscarriages should be reported and handled as 
SAEs  (Section  8.4.1, Reporting of serious adverse events).  Elective abortions without 
complications should not be handled as AEs.  The outcome of all pregnancies (spontaneous 
miscarriage, elective termination, ectopic pregnancy, normal birth , or congenital abnormality) 
should be followed up and documented even if the subject  was discontinued from the study. 
[IP_ADDRESS] Paternal exposure  
Male subjects should refrain from fathering a child or donating sperm for the duration of the 
treatment period an d for [ADDRESS_1002618]’s partners is not considered to be an AE.  However, the outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital abnormality) must be followed up, documented, and reported to  
 using the Pregnancy Notification and 
Outcome Form .  Congenital abnormalities/birth defects and spontaneous miscarriages should 
be reported and handled as SAEs ( Section 8.4.1, Reporting of serious adver se events).  
The outcome of any conception occurring from the date of administration of IP  until 
5 half -lives of AZD40 41 or 12 weeks (whichever is longer) after the last administration of IP 
must be followed up, documented, and reported to  
 
 Overdose 
If a subject receives study medication in excess of that prescribed by [CONTACT_64106], this will be 
considered an overdose.  There are no data on overdosing with AZD4041, as this is the first 
clinical study of AZD4041.  There is no known specific antidote.  In case of known or suspected overdose, symptomatic treatment as well as monitoring of vital functions should be 
performed as per the judgement of the Investigator.   
• An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE modules in the CRF and on the Overdose eCRF module. 
• An overdose without associated symptoms is only reported on the Overdose CRF module 

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  52 of 78  
 • In the event of an overdose, the Medical Monitor or physician designate should be 
contact[CONTACT_733757].  A description of 
the treatment administered for the overdose as well as the subject’s clinical course will be recorded.  In the event of an overdose,  
 
• For overdoses associated with an SAE, the standard reporting procedures and timelines apply ; see Section 8.3.2 and Section 8.4.1.   
 
 Medication error  
Medication errors with A straZeneca IP are collected in all studies where medication error is 
possible.  Refer to the Pre -Startup Safety Review  (PSSR ) or other appropriate project 
document for specific considerations for collection of medication errors. 
For guidance, refer to the A straZeneca Standard O perating Procedure (SOP) ‘Reporting of 
Individual Safety Events in Clinical Studies’. If a medication error occurs in the course of the study, the Investigator or other site personnel 
informs the appropriate [COMPANY_008] representatives within 1 day; ie, immediately but no later 
than 24 hours of when the Investigator  becomes aware of it.  
The designated [COMPANY_008] representative works with the Investigator to ensure that all relevant information is completed within 1 (Initial Fatal/Life -Threatening or follow-up 
Fatal/Life -Threatening) or 5 (other serious initial and follow- up) calendar days if there is a 
SAE  associated with the medication error (see Section 8.3.2) and within 30 days for all other 
medication errors.  
The definition of a medication error can be found in Appendix B . 
 Management of IP-related toxicities 
The Investigator is responsible for ensuring that expertise and facilities are available for the management of all suspected IP -related toxicities in accordance with local procedures and 
accepted standards of medical practice.  There is no specific antidote to AZD4041.  In case of 
suspected IP -related toxicity, an appropriate level of vital sign monitoring should be instituted; 
symptomatic and supportive treatment should be provided according to the judgement of the Investigator.  Treatment of suspected IP -related toxicity may be guided by [CONTACT_733758], and referral to a specialist cent er may be warranted.  
Any case of suspected IP -related toxicity should be reported as an AE ( Section 8.3) or SAE 
(Section 8.4.1).  

Clinical Study Protocol Amendment [ADDRESS_1002619] of the following core members: 
• Principal Investigator (Chair, voting member) 
• [COMPANY_008] Lead Physician or delegate (must be a physician) (voting member)  
• CRO Medical Monitor (voting member) 
• CRO Project Manager (nonvoting member) 
• Pharmacokineticist (nonvoting member)  
 
The SRC may also request to have attendance of, or offline support and input from the 
following functions, as required: 
• [COMPANY_008] and/or CRO Pharmacokin etic Scientists  
• [COMPANY_008] Team Pharmacometrician  
• CRO and [COMPANY_008] Statisticians  
• [COMPANY_008] and/or CRO Medical Specialists ( eg, neurologist, AZ ECG Cent er 
cardiologists, etc .) 
• [COMPANY_008] and /or CRO Patient Safety Physician.  
 
The SRC voting members will make the decision for the next dose level or whether to stop the 
study after reviewing all the pertinent safety and PK data.  Other internal or external experts 
may be invited to participate in the review or may be consulted. 
If consensus among the voting SRC members cannot be reached then the PI , who has the 
ultimate responsibility for the safety of the subjects, will make the final decision on the next 
dose level or whether to stop the study.  In any event, dose escalation can only occur if agreed 
by [CONTACT_978]. 
The decisions of the SRC on the next dose level will be documented and provided to all the appropriate parties involved with the study, including the Pharmacist, to enable IP preparation 
for the next scheduled dosing day. 
Initially the data will be reviewed blinded, but if the PI [INVESTIGATOR_733739] a safety concern, data from individual subjects or the entire cohort may be unblinded to 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  54 of 78  
 enable decision -making .  Before breaking the code, the potential decis ions and actions should 
be determined .  The code will be broken according to local SOPs .  The SRC may stop dose 
escalation at any time if the SRC determines that dose escalation would pose undue risk to 
subjects .  If dose escalation is not stopped, the SRC may recommend ascending to the planned 
next higher dosage level cohort, ascending to a dosage level lower than the planned next higher dosage level cohort, repeat dosing at the current dosage level, or continuing with a 
lower dose than the current dosage level.   
Following review of data from a cohort of subjects, the timing of assessments and/or blood 
samples may be adjusted for subsequent cohorts. 
Additional assessment or sampling times may be added if indicated by [CONTACT_26739].  
The following accumulated blinded safety data up to and including Day  [ADDRESS_1002620]-dose 
follow- up data for a given cohort, as available, will be reviewed by [CONTACT_12217]:  
• AE profile , including description, frequency, intensity, onset, duration, and Investigator 
assessm ent of the relationship to IP 
• SAE listings and case narratives  
• Vital sign parameters, including BP, orthostatic BP , and pulse rate  
• 12-lead (paper) ECG assessments and interval data  
• Safety report containing an analysis and review of dECG data, to be provide d by [CONTACT_733759]  
• Clinical laboratory test results  
• PK data 
• Testosterone, LH, FS H, and i nhibin B assessment results for male subjects  
 
Full SRC details are described in the SRC Charter.  
8.[ADDRESS_1002621] samples .  The results from the evaluation will not be reported in the CSR, but separately 
in a Bioanalytical Report.  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  55 of 78  
 
 Metabolite identification in plasma  
Following determination of drug concentration and appropriate assessment of incurred sample 
reproducibility, residual or back-up plasma PK  samples may be utilized for inve stigative  
metabolite identification studies.   Utilizi ng appropriate analytical  methods, this exploratory 
approach will aim to identify major circulating metabolites of AZD4041 in plasma.  The 
results from the evaluation will not be reported in the CSR, but reported separately in a 
Metabolite Identification Report.  
 Storage and destruction of pharmacokinetic samples 
Pharmacokinetic samples will be disposed of after the Bioanalytical Report finaliz ation  or 
6 months after issuance of the draft Bioanalytical Report (whichever is earlier), unless requested for future analyses .  Left-over PK samples may be used for analysis of safety, 
efficacy , or biomarker laboratory parameters if samples drawn for that purpose at the same 
time point were insufficient for the analyses needed.  
Pharmacokinetic samples may be disposed of or destroyed and anonymiz ed by [CONTACT_76435].  
Additional analyses may be conducted on the anonymized, pooled PK samples to further 
evaluate and validate the analytical method .  Any results from such analyses may be reported 
separately from the CSR.  
8.6 Pharmacodynamics  
To characterize the PD relationship between drug exposure and QT interval, an 
exposure- response (E -R) analysis may be conducted with data from this study alone or in 
combination with other studies as appropriate, with a pre- specified workflow described in a 
separate technical document for the QTcF parameter, as part of the cardiac safety evaluation and with the intention to obtain a Thorough QT study substitute.  The result of the E- R 
analysis may not be included in the main study report. 
[ADDRESS_1002622] 
deviation, minimum, median, and maximum, while for continuous PK variables, descriptive summary statistics will also include geometric mean and arithmetic coefficient of variation .  
Descriptive summary statistics for categorical data will include frequency and proportion .  
Tests of significance of group difference (drug dose versus placebo) on change from baseline 
in safety variables will also be performed .  Model- based approaches will be used, if 
appropriate. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  56 of 78  
 9.1 Statistical hypotheses  
Based on the predicted human exposure following a  of AZD4041, a  
exposure margin to free C max and a  exposure margin to free AUC 0-inf when compared 
to the corresponding toxicokinetic parameters for dog NOAEL dose level in male dogs is 
predicted.  For a , the corresponding free C max and free AUC 0-inf 
exposure margins would be , respectively. 
9.2 Sample size determination  
Due to the exploratory nature of the study, sample size is not based on formal statistical considerations but is based primarily on a desire to obtain sufficient safety and tolerability information while exposing as few subjects as possible to the investigational treatment.  
9.3 Populations for analyses  
For purposes of analysis, the following populations are defined: 
Population Description  
PK analysis set  All subjects who received IP and for whom PK data are available  
Safety analysis set  All subjects who received  at least [ADDRESS_1002623] -dose 
data are available   
 
9.4 Statistical analyses  
A comprehensive statistical analysis plan (SAP) will be developed and finaliz ed before 
database lock and will describe the subject populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data.  This section is a summary 
of the planned statistical analyses of the primary and secondary endpoints.  Any  deviations 
from  this plan  will be reported  in the CSR. 
 Pharmacokinetic analyses 
Standard PK variables for a single ascending dose study will be derived. 
• Cmax 
• Tmax 
• AUC 0-t 
• AUC 0-inf 
• t1/2λz 
• CL/F  (apparent total clearance of the drug from plasma after oral administration)  
• Vss/F (apparent volume of distribution at steady state after non-intravenous 
administration)  

Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  57 of 78  
  
 Safety analyses 
All safety analyses will be performed on the Safety analysis set .  Specific methods will be 
described in the SAP . 
[IP_ADDRESS] Safety and tolerability 
Adverse events will be listed and summariz ed by [CONTACT_733760] , and by [CONTACT_71397].  The presentation 
period of AEs will be the time from first dose to follow -up.  
Vital signs, body temperature, body weight and BMI, clinical laboratory measures, and dECG 
interval data will be summarized using descriptive statistics by [CONTACT_733761] (eg, visit number, date, and time).  
Individual data for vital signs, body weight and BMI, clinical laboratory measures, dECG 
intervals, overall pECG assessments (made by [CONTACT_737]), and physical examination results will be flagged and listed for any potentially clinically important (PCI) values for each 
subject according to predetermined PCI criteria.  
Project -specific reference limits will be used in the statistical analysis.  When project- specific 
reference lim its are not available, the reference limits of the local laboratory will be used.  
[IP_ADDRESS] Pharmacokinetics  
AZD4041 serum concentration data will be summarized using descriptive statistics by 
[CONTACT_733762].  Individual and mean AZD4041 serum 
concentration versus time data will be plotted by [CONTACT_71397].  
PK parameters of AZD4041 will be summarized using descriptive statistics by [CONTACT_108302].   Dose proportionality and linearity of PK exposure parameters (AUC and C
max) will 
be evaluated using a regression (power) model relating log transformed C max and AUC 
parameters to the log transformed dose.  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  58 of 78  
 10 REFERENCES  
American Psychiatric Association 2013  
American Psychiatric Association .  Diagnostic and Statistical Manual of Mental Disorders 
(DSM -5).  Fifth Ed .  Arlington, VA: American Psychiatric Association 2013. 
Arundel [ADDRESS_1002624] biological actions of orexin -a in rat testis .  Endocrinology 
2005;146(12):5164-75. 
Benowitz 2009 
Benowitz NL.  Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics .  Annu Rev Pharmacol Toxicol 2009;49:57-71. 
Boutrel et al 2005 
Boutrel B, Kenny PJ, Specio SE, Martin -Fardon R, Markou A, Koob GF, et al.  Role for 
hypocretin in mediating stress -induced reinstatement of cocaine-seeking behavior.  Proc Natl 
Acad Sci [LOCATION_003] 2005;102(52):[ZIP_CODE]-73. 
Cahill et al [ADDRESS_1002625] Rev 2011;(2):CD006103. 
Cahill et al 2013 
Cahill K, Stevens S, Perera R, Lancaster T.  Pharmacological interventions for smoking cessation: an overview and network meta- analysis.  Cochr ane Database Syst Rev.  
2013;5:CD009329. 
Catz et al 2011 
Catz SL, Jack LM, McClure JB, Javitz HS, Deprey M, Zbikowski SM, et al.  Adherence to varenicline in the COMPASS smoking cessation intervention trial.  Nicotine Tob Res 2011;13(5):361-8. 
Coe et al 2005 
Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.  J Med Chem 
2005;48(10):3474-7. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  59 of 78  
 Doll et al 1994 
Doll R, Peto R, Wheatley K, Gray R, Sutherland I .  Mortality in relation to smoking: 40 years ’ 
observations on male British doctors.  BMJ 1994;309(6959):901-11. 
Doll et al 2004 
Doll R , Peto R, Boreham J, Sutherland I.  Mortality in relation to smoking: 50 years ’ 
observations on male British doctors.  BM J 2004;328(7455):1519. 
eMC 2018 
Electronic Medicines Compendium (eMC) .  Summary of Product Characteristics for Champix 
(varenicline) .  Available at:  https://www.medicines.org.uk/emc/product/266/smpc/print . 
Ezzati  and Lopez 2003 
Ezzati M , Lopez AD.  Estimates of global mortality attributable to smoking in 2000 .  Lancet 
2003;362(9387):847-52. 
Goodchild et al 2018 
Goodchild M, Nargis N, Tursan d’ Espaignet E .  Global economic cost of smoking- attributable 
diseases .  Tob Control 2018 Jan;27(1):58-64. 
Gotter et al 2016 
Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, et, al .  Orexin -2 receptor 
antagonism is sufficient to promote NREM and REM sleep from mouse to man.  Sci Rep 2016 
Jun3;6:[ZIP_CODE]. 
Hakovirta et al 1999 
Hakovirta H, Yan W, Kaleva M, Zhang F, Vänttinen K, Morris P, et al.  Function of stem cell 
factor as a survival factor of spermatogonia and localization of messenger ribonucleic acid in 
the rat seminiferous epi[INVESTIGATOR_2130].   Endocrinology 1999;140(3):1492-98. 
Harris et al [ADDRESS_1002626] seeking .  Nature 2005;437(7058):556-9. 
Jha et al [ADDRESS_1002627]-century hazards of smoking and benefits of cessation in the [LOCATION_002].  N Engl J Med 
2013;368(4):341-50. 
Kaufmann et al [ADDRESS_1002628]-539313: a novel selective orexin-[ADDRESS_1002629].  Clin 
Pharmacol Ther 2019;105(suppl S1):s37. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  60 of 78  
 Kenny 2011 
Kenny PJ .  Tobacco dependence, the insular cortex and the hypocretin connection.  Pharmacol 
Biochem  Behav 2011;97(4):700-7. 
Knight et al [ADDRESS_1002630]-e ffectiveness of an extended course 
(12 + 12 w eeks) of varenicline compared with other available smoking c essation strategies in 
the [LOCATION_002]: an extension and update to the BENESCO model.  Value Health  
2010;13(2):209-14. 
Kodadek and Cai [ADDRESS_1002631] 
2010;6(8):1366-75. 
Ligouri et al 2018 
Ligouri G, Squilliacioti C, Assisi L, Pelagalli A, Vittoria A, Costagliola A, et al.  Potential 
role of orexin A binding the receptor 1 for orexins in normal and cryptorchid dogs.  BMC Vet 
Res 2018;14:55. 
Lim et al 2010 
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al .  A comparative 
risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor 
clusters in 21 regions, 1990- 2010: a systematic analysis for the Global Burden of Disease 
Study 2010.  Lancet 2012;380(9859):2224-60. 
Mathers and Loncar 2006 
Mathers CD, Loncar D.  Projections of global mortality and burden of disease from 200s to 
2030.  PLoS Med 2006;3(11):e442. 
Murray  and Lopez 1997 
Murray CJ , Lopez AD.  Alternative projections of mortality and disability by [CONTACT_102950] 
1990-2020: Global Burden of Disease Study.  Lancet 1997;349(9064):1498-504. 
O’Connor et al 2010 
O’Connor EC, Parker D, Rollema H, Mead AN.  The alpha4beta2 nicotinic acetylcholine-
receptor partial agonist varenicline inhibits both nicotine self -administration following 
repeated dosing and reinstatement of nicotine seeking in rats.  Psychopharmacology (Berl) 2010;208(3):365-76. 
Peto  et al  2000 
Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R.  Smoking, smoking cessation, and 
lung cancer in the [LOCATION_006] since 1950: combination of national statistics with two case-control 
studies.  BMJ 2000;321(7257):323-9. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  61 of 78  
 Sakurai et al 1998 
Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H et al.  Orexins and 
orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior .  Cell 1998;92(4):573-85. 
Salvadore et al 2019 
Salvadore G,  Brooks S, Cathy B, et al.  JNJ -61393215 in male healthy volunteers.  74th Annu 
Meet Soc Biol Psychiatry (SOBP) [ADDRESS_1002632] F13. 
Samson et al 2007 
Samson WK, Bagley SL, Ferguson AV, White MM.  Hypocretin/orexin type 1 receptor in brain: role in cardiovascular control and the neuroendocrine response to immobilization stress.  Am J Physiol Regul Integr Comp Physiol 2007 Jan;292(1):R382-7. 
Stolerman and Jarvis 1995 
Stolerman IP, Jarvis MJ, The scientific case that nicotine is addictive .  Psychopharmacology 
(Berl) 1995;117(1):2-10. 
Willie et al [ADDRESS_1002633] 
narcolepsy syndromes in Orexin receptor- 2 and Orexin null mice: molecular genetic 
dissection of Non- REM and REM sleep regulatory processes .  Neuron 2003;38(5):715-30. 
Yan et al 1999 
Yan W,  Linderborg J, Suominen J, Toppari J.  Stage -specific regulation of stem cell factor  
gene expression  in rat seminiferous epi[INVESTIGATOR_2130].  Endocrinology 1999;140(3):1499-1504. 
Yan et al 2000 
Yan W, Suominen J, Toppari J.  Stem cell factor protects germ cells from apoptosis in vitro.  
J Cell Sci 2000;113:161-8. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  62 of 78  
 11 SUPPORTING DOCUMENTATION AND OPERATIONAL  
CONSIDERATIONS  
Appendix  A Regulatory, ethical and study oversight considerations  
A 1 Regulatory and ethical considerations  
This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines  
• Applicable International Conference of Harmonisation ( ICH) Good Clinical Practice 
(GCP) Guidelines 
• Applicable laws and regulations 
 
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents 
(eg, advertisements) must be submitted to an Institutional Review Board/Instutional Ethics 
Committee (IRB/IEC) by [CONTACT_22843]/IEC before 
the study is initiated.  
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study subject s. 
The investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/IEC  
• Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures 
• Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical 
studies (if applicable), and all other applicable local regulations  
 
The study will be performed in accordance with the [COMPANY_008] policy on Bioethi cs and 
Human Biological Samples.  
A 2 Financial disclosure  
Investigators and sub- investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  63 of 78  
 certification or disclosure statements to the appropriate regulatory authorities .  Investigators 
are responsible for providing information on financial interests during the course of the study 
and for 1 year after completion of the study. 
A 3 Informed consent process  
The inves tigator or his/her representative will explain the nature of the study to the subject  and 
answer all questions regarding the study.   
Subject s must be informed that their participation is voluntary .  Subject s will be required to 
sign a statement of informe d consent that meets the requirements of [ADDRESS_1002634] (HIPAA) 
requirements, where applicable, and the IRB/IEC or study cent er. 
The medical record must include a statement that written informed consent was obtained 
before the subject  was enrolled in the study and the date  the written consent was obtained.  
The authorized person obtaining the informed consent must also sign the ICF. 
Subject s must be re-consented to the most current version of the ICF(s) during their 
participation in the study.  
A copy of the ICF(s) must be provided to the subject . 
If a subject  declines to participate in any voluntary exploratory genetic research component of 
the study, there will be no penalty or loss of benefit to the subject  and he/she will not be 
excluded from other aspects of the study. Subjects who are re- prescreened are required to sign a new brief ICF.  The brief ICF is used to 
obtain subject  consent for sUA, eGFR, and UACR assessments.  Subjects who are rescreened 
are requir ed to sign a new full ICF.  The full ICF is the master ICF for the study.  
The ICF will contain a separate section that addresses the use of remaining mandatory 
samples for optional exploratory research .  The investiga tor or authoriz ed designee will 
explain to each subject  the objectives of the exploratory research .  Subject s will be told that 
they are free to refuse to participate and may withdraw their consent at any time and for any reason during the storage period.  The subject  will give a separate agreement to allow any 
remaining specimens to be used for exploratory research .  Subjects who decline to participate 
in this optional research will indicate this in the ICF .  If a subject withdraws consent to the use 
of donated biological samples, the samples will be disposed of/destroyed, and the action documented.  If samples already have been analy zed at the time of the request , [COMPANY_008] 
will not be obliged to destroy the results of this research.  
Clinical Study Protocol Amendment [ADDRESS_1002635]  records or data 
sets transferred to the sponsor will contain only the identifier; subject  names or any 
information which would make the subject  identifiable will not be transferred.  
The subject  must be informed that his/her personal study- related data will be used by [CONTACT_20004].  The level of disclosure must also be 
explained to the subject . 
The subje ct must be informed that his/her medical records may be examined by [CONTACT_11000], by [CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
A [ADDRESS_1002636]  Safety .  Issues identified will be 
addressed; for instance this could involve amendments to the Clinical Study Protocol and letters to Investigators.  
Safety review  committee  (SRC)  
An SRC will review data from each cohort before progression to the next cohort occurs. 
A 6 Dissemination of clinical study data  
A description of this clinical trial will be available on http://astrazenecaclinicaltrials.com and http://www.clinicaltrials.gov as will the summary of the main study results when they are 
available.  The clinical trial and/or summary of main study results may also be available on 
other websites according to the regulations of the countries in which the main study is conducted. 
A [ADDRESS_1002637]  data relating to the study will be recorded on printed or e lectronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory d ata).  The investigator is 
responsible for verifying that data entries are accurate and correct by [CONTACT_1189].   
The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF.   
Clinical Study Protocol Amendment [ADDRESS_1002638] permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents. 
The sponsor or designee is responsible for the data management of this study including quality 
checking of the data.  
Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by [CONTACT_733763], complete, and verifiable from source 
documents; that the safety and right s of subject s are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.  
Records and documents, including signed ICFs, pertaining to the conduct of this study must 
be retained by [CONTACT_1732] [ADDRESS_1002639] and substantiate the 
integrity of the data collected .  Source documents are filed at the investigator’s site.  
Data reported on the CRF that are transcribed from source documents must be consistent with 
the source documents or the discrepancies must be explained .  The investigator may need to 
request previous medical records or transfer records, depending on the study .  Also, current 
medical records must be available.  
All information in original records and certified copi[INVESTIGATOR_733740] f indings, 
observations, or other activities in a clinical study necessary for the reconstruction and evaluation of the study are defined as source documents.  Source data are contained in source 
documents (original records or certified copi[INVESTIGATOR_014]). 
Clinical Study Protocol Amendment [ADDRESS_1002640] a causal 
relationship with this treatment.  An AE can therefore be any unfavourable and unintended 
sign (eg, an abnormal laboratory finding), symptom (eg, nausea, chest pain), or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. 
The term AE is used to include both serious and non-serious AEs and can include a 
deterioration of a pre- existing medical occurrence .  An AE may occur at any time, including 
run-in or washout periods, even if no Study treatment has been administered.  
B 2 Definitions of serious adverse event  
An SAE is an AE occurring during any study phase (ie, run-in, treatment, washout, follow-
up), that fulfils one or more of the following criteria: 
• Results in death  
• Is immediately life -threatening 
• Requires in -patient  hospi[INVESTIGATOR_8686]  
• Results in persistent or significant disability or incapacity  
• Is a congenital abnormality or birth defect 
• Is an important medical event that may jeopardise th e subject  or may require medical 
treatment to prevent one of the outcomes listed above. 
 
B 3 Life-threatening  
‘Life -threatening’ means that the subject  was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
subject ’s death.  ‘Life-threatening’ does not mean that had an AE occurred in a more severe 
form it might have caused death ( eg, hepatitis that resolved without hepatic failure).  
B [ADDRESS_1002641]  treatment in an emergency room is not in itself a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal edema) .  Hospi[INVESTIGATOR_2144]/or surgical 
operations planned before or during a study are not considered AEs if the illness or disease existed before the subject  was enrolled in the study, provided that it did not deteriorate in an 
unexpected way during the study. 
Clinical Study Protocol Amendment [ADDRESS_1002642] drug does not mean that it is an important medical event; medical 
judgement must be used. 
• Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatment  
• Hepatotoxicity caused by [CONTACT_76475] (acetaminophen) overdose requiring treatment with N-acetylcysteine  
• Intensive treatment in an emergency room or at home for allergic bronchospasm  
• Blood dyscrasias (eg , neutropenia or anemia requiring blood transfusion, etc.) or 
convulsions that do not result in hospi[INVESTIGATOR_1838]  
• Development of drug dependency or drug abuse 
 
B 6 Intensity rating scale:  
1 mild (awareness of sign or symptom, but easily tolerated).  Usually transient and may 
require only minimal treatment or therapeutic intervention.  The event does not generally 
interfere with usual activities of daily living.  
2 moderate (discomfort sufficient to cause interference with normal activities) .  Usually 
alleviated with additional specific therapeutic intervention.  The event interferes with 
usual activities of daily living, causing discomfort, but poses no significant or permanent risk of harm to the subject. 
3 severe (incapacitating, with inability to perform normal activities) .  Interrupts usual 
activities of daily living, or significantly affects clinical status, or may require intensive 
therapeutic intervention. 
 
It is important to distinguish between serious and severe AEs.  Severity is a measure of 
intensity whereas seriousness is defined by [CONTACT_73010] B 2.  An AE of severe intensity need not necessarily be considered serious .  For example, nausea that persists for 
several hours may be considered severe nausea, but not a SAE unless it meets the criteria shown in Appendix B 2.  On the other hand, a stroke that results in only a limited degree of disability may be considered a mild stroke but would be a SAE when it satisfies the criteria shown in Appendix B 2. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  68 of 78  
 B 7 A Guide to Interpreting the Causality Question  
When making an assessment of causality consider the following factors when deciding if there 
is a ‘reasonable possibility’  that an AE may have been caused by [CONTACT_33641].  
• Time Co urse.  Exposure to suspect drug.  Has the subject  actually received the suspect 
drug?  Did the AE occur in a reasonable temporal relationship to the administration of the 
suspect drug? 
• Consistency with known drug profile.  Was the AE consistent with the previous 
knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same pharmacological class? Or could the AE be anticipated from its pharmacological properties? 
• De-challenge experience.  Did the AE resolve or improve on stoppi[INVESTIGATOR_72918]? 
• No alternative cause.  The AE cannot be reasonably explained by [CONTACT_230614], other drugs, other host or environmental factors. 
• Re-challenge experience.  Did the AE reoccur if the suspected drug was reintroduced 
after having been stopped? [COMPANY_008] would not normally recommend or support a 
re-challenge. 
• Laboratory tests .  A specific laboratory investigation (if performed) has confirmed the 
relationship . 
 
In difficult cases, other factor s could be considered such as: 
• Is this a recognized  feature of overdose of the drug? 
• Is there a known mechanism?  
 Causality of ‘related’ is made if following a review of the relevant data, there is evidence for a 
‘reasonable possibility’  of a causal relati onship for the individual case.  The expression 
‘reasonable possibility’ of a causal relationship is meant to convey, in general, that there are 
facts (evidence) or arguments  to suggest a causal relationship. 
The causality assessment is performed based on the available data including enough information to make an informed judgment.  With limited or insufficient information in the 
case, it is likely that the event(s) will be assessed as ‘not related’.  
Causal relationship in cases where the disease under stud y has deteriorated due to lack of 
effect should be classified as no reasonable possibility. 
Clinical Study Protocol Amendment [ADDRESS_1002643] ug that either causes harm to the participant 
or has the potential to cause harm to the participant.   
A medication error is not lack of efficacy of the drug, but rather a human or process related 
failure while the drug is in control of the study site staff or participant.  
Medication error includes situations where an error: 
• occurred  
• was identified and intercepted before the participant received the drug  
• did not occur, but circumstances were recognized that could have led to an error 
 
Examples of events  to be reported in clinical studies as medication errors: 
• Drug name [CONTACT_2976] 
• Dispensing error eg,  medication prepared incorrectly, even if it was not actually given to 
the participant  
• Drug not administered as indicated, for example, wrong route or wrong site of 
administration  
• Drug not taken as indicated eg,   tablet dissolved in water when it should be taken as a 
solid tablet  
• Drug not stored as instructed eg,   kept in the fridge when it should be at room temperature  
• Wrong participant received the medicat ion 
• Wrong drug administered to participant 
 
Examples of events that do not  require reporting as medication errors in clinical studies: 
• Participant accidentally missed drug dose(s) eg,  forgot to take medication  
• Accidental overdose (will be captured as an overdose)  
• Participant failed to return unused medication or empty packaging 
• Errors related to background and rescue medication, or standard of care medication in 
open label studies, even if an AZ product 
 
Medication errors are not regarded as AEs but AEs may occur as a consequence of the 
medication error.  
Clinical Study Protocol Amendment [ADDRESS_1002644] samples – International 
Airline Transportation Association 6.2 Guidance Document  
The International Airline Transportation Association (IATA) classifies biohazardous agents 
into 3 categories 
(http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substances.htm) .  For 
transport purposes, the classification of infectious substances ac cording to risk groups was 
removed from the Dangerous Goods Regulations in the 46th edition (2005) .  Infectious 
substances are now classified either as Category A, Category B , or Exempt .  There is no dire ct 
relationship between Risk Groups and Categories A and B. 
Category A Infectious Substances are infectious substances in a form that, when exposure to 
it occurs, is capable of causing permanent disability, life- threatening or fatal disease in 
otherwise healthy humans or animals .  Category A pathogens are, eg, Ebola, Lassa fever 
virus: 
• are to be packed and shipped in accordance with IATA Instruction 602. 
 
Category B Infectious Substances are infectious Substances that do not meet the criteria for 
inclusion in Category A .  Category B pathogens are eg, Hepati tis A, B, C, D, and E viruses, 
Human immunodeficiency virus types 1 and 2.  They are assigned the following UN number  
and proper shippi[INVESTIGATOR_72919]: 
• UN 3373 – Biological Substance, Category B  
• are to be packed in accordance with UN3373 and IATA 650 
Exempt – all other materials with minimal risk of containing pathogens  
• Clinical trial samples will fall into Category B or exempt under IATA regulations  
• Clinical trial samples will routinely be packed and transported at ambient  
• Temperature in IATA 650 compliant packagi ng 
(http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substances.htm ) 
• Biological samples transported in dry ice require additional dangerous goods specification for the dry -ice content  
• IATA compliant courier and packaging materials should be used for packing and transportation and packing should be done by [CONTACT_73013], as applicable 
• Samples routinely transported by [CONTACT_733764] a safe and appropriate way to contain 
any risk of infection or contamination by [CONTACT_244991]/containment materials at all times .  The IATA [ADDRESS_1002645] or rail transport is used. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  71 of 78  
 Appendix  C Actions required in cases of increases in liver biochemistry 
and evaluation of Hy’s Law  
C 1 Introduction  
This Appendix describes the process to be followed in order to identify and appropriately 
report Potential Hy’s Law (PHL) cases and Hy’s Law (HL) cases .  It is not intended to be a 
comprehensive guide to the management of elevated liver biochemistries.  
During the course of the study the Investigator will remain vigilant for increases in liver 
biochemistry .  The Investigator is responsible for determining whether a subject  meets PHL 
criteria at any point during the study.  
All sources of laboratory data are appropriate for the determination of PHL and HL events; this includes samples taken at scheduled study visits and other visits including central and all local laboratory evaluations even if collected outside of the study visits; for example, PHL criteria co uld be met by [CONTACT_96724] a central laboratory and/or  elevated TBL from 
a local laboratory.  
The Investigator will also review Adverse Event data  (for example, for AEs that may indicate elevations in liver biochemistry) for possible PHL events. 
The Investigator participates, together with [COMPANY_008] clinical project representatives, in 
review and assessment of cases meeting PHL criteria to agree whether HL criteria are met .  
HL criteria are met if there is no alternative explanation for the elev ations in liver 
biochemistry other than drug-induced liver injury (DILI) caused by [CONTACT_7198] (IP). 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting SAEs and AEs according to the outcome of the review and assessment in line with 
standard safety reporting processes.  
C 2 Definitions 
Potential Hy’s Law (PHL)  
Aspartate aminotransferase ( AST) or alanine aminotransferase ( ALT) ≥3× upper limit of 
normal (ULN) together with  total bilirubin ( TBL) ≥2×ULN at any point during the study 
following the start of study medication   irrespective of an increase in alkaline phosphatase 
(ALP) . 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  72 of 78  
 Hy’s Law (HL) 
AST or ALT ≥3 × ULN  together with TBL ≥2  ×ULN, where no other reason, other than the 
IP, can be found to explain the combination of increases; eg, elevated ALP indicating 
cholestasis, viral hepatitis, another drug. 
For PHL and HL the elevation in transaminases must precede or be coincident with (ie, on the 
same day) the elevation in TBL, but there is no specified time frame within which the 
elevations in transaminases and TBL must occur. 
C 3 Identification of potential Hy’s Law cases  
In order to identify cases of PHL it is important to perform a comprehensive review of laboratory data for any subject  who meets any of the f ollowing identification criteria in 
isolation or in combination: 
• ALT ≥3  × ULN  
• AST ≥3  × ULN  
• TBL ≥2  × ULN  
 
Central laboratories being used:  
When a subject  meets any of the PHL identification criteria, in isolation or in combination, the 
central laboratory will immediately send an alert to the Investigator (and also to the 
[COMPANY_008] representative).  
The Investigator will also remain vigilant for any local laboratory reports where the PHL 
identification criteria are met, where this is the case the Investigator will:  
• Notify the [COMPANY_008] representative  
• Request a repeat of the test (new blood draw) by [CONTACT_591354] 
• Complete the appropriate unscheduled CRF module(s) with the original local laboratory 
test result 
 
When the identification criteria are met from central or local laboratory results the Investigator 
will without delay:  
• Determine whether the subject  meets PHL criteria (see Appendix C 2 for definition) by 
[CONTACT_48886] (including both central and local 
laboratory results) 
 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  73 of 78  
 Local laboratories being used: 
The Investigator will without delay review each new laboratory report and if the identification 
criteria are met will:  
• Notify the [COMPANY_008] representative  
• Determine whether the subject  meets PHL criteria (see Appendix C 2 for definition) by 
[CONTACT_48886]  
• Promptly enter the laboratory data into the laboratory C RF 
 
C 4 Follow -up 
C 4.1 Potential Hy’s Law criteria not met  
If the subject  does not meet PHL criteria the Investigator will: 
• Inform the [COMPANY_008] representative that the subject  has not met PHL criteria.  
• Perform follow -up on subsequent laboratory results according to the guidance provided in 
the Clinical Study Protocol.  
 
C 4.2 Potential Hy’s Law criteria met  
If the subject  does meet PHL criteria the Investigator will: 
• Notify the [COMPANY_008] representative who will then inform the central Study Team  
• Within 1  day of PHL criteria being met, the Investigator will report the case as an SAE of 
Potential Hy’s Law; serious criteria ‘Important medical event’ and causality assessment 
‘yes/related’ according to CSP process for SAE reporting.  
• For subjects that met PHL criteria prio r to starting IMP, the investigator is not required to 
submit a PHL SAE unless there is a significant change# in the subject’ s condition  
• The Study Physician contacts the Investigator, to provide guidance, discuss and agree an 
approach for the study subject s’ follow -up and the continuous review of data. 
• Subsequent to this contact [CONTACT_48887]: 
− Monitor the subject  until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medical ly 
indicated.  Complete the follow-up SAE Form as required. 
− Investigate the etiology of the event and perform diagnostic investigations as 
discussed with the Study Physician.  This includes deciding which the tests available 
in the Hy’s law lab kit should be used.  
− Complete the 3 Liver CRF Modules as information be comes available  
 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  74 of 78  
 C 5 Review and assessment of potential Hy’s Law cases  
The instructions in this section should be followed for all cases where PHL criteria are met. 
As soon as possible after the biochemistry abnormality was initially detected, the Study 
Physi cian contacts the Investigator in order to review available data and agree on whether 
there is an alternative explanation for meeting PHL criteria other than DILI caused by [CONTACT_33249], 
to ensure timely analysis and reporting to health authorities within [ADDRESS_1002646] and TBL  elevations, 
a determination of whether the alternative explanation is an AE will be made and 
subsequently whether the AE meets the criteria for a SAE: 
• If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate CRF 
• If the alternative explanation is an AE/SAE: update the previously- submitted Potential 
Hy’s Law SAE and AE CRFs accordingly with the new information (reassessing event 
term; causality and seriousness criteria) following the AZ standard processes. 
 
If it is agreed that there is no explanation that would explain the ALT or AST and TBL 
elevations other than the IP: 
• Send an updated SAE (report term ‘Hy’s Law’) according to [COMPANY_008] standard 
processes.   
− The ‘Medically Important’ serious criterion should be used if no other serious criteria 
apply 
− As there is no alternative explanation for the HL case, a causali ty assessment of 
‘related’ should be assigned. 
 
If there is an unavoidable delay of over 15 calendar days in obtaining the information 
necessary to assess whether or not the case meets the criteria for HL, then it is assumed that 
there is no alternative ex planation until such time as an informed decision can be made: 
• Provide any further update to the previously submitted SAE of Potential Hy’ s Law, 
(report term now ‘Hy’s Law case’ ) ensuring causality assessment is related to IP and 
seriousness criteria is me dically important, according to CSP process for SAE reporting. 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  75 of 78  
 • Continue follow-up and review according to agreed plan.  Once the necessary 
supplementary information is obtained, repeat the review and assessment to determine 
whether HL criteria are still me t.  Update the previously-submitted PHL SAE report 
following the CSP process for SAE reporting, according to the outcome of the review amending, the reported term if an alternative explanation for the liver biochemistry elevations is determined.  
 
References 
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al .  Case 
definition and phenotype standardization in drug-induced liver injury.  Clin Pharmocol Ther 
2011; 89(6):806-815. 
FDA Guidance for Industry  Drug-induced liver injury: Prema rketing clinical evaluation .  
[ADDRESS_1002647]  aspartate aminotransferase  
AUC  area under the curve  
AUC 0-inf extrapolation of the area under the curve from time 0 to infinity  
AV atrioventricular  
BBB  bundle branch block 
BMI  body mass index 
BP blood pressure  
CL/F  apparent total clearance of the drug from plasma after oral administration  
Ceff free efficacious exposure  
Cmax maximum (peak) plasma drug concentration  
CONSORT  Consolidated Standards of Reporting Trials  
COVID -19 Coronavirus disease of 2019  
CRF  Case R eport Form (electronic/paper)  
CRO  clinical research organization  
CRU  clinical research unit  
CSP clinical study protocol  
CSR  clinical study report 
CV cardiovascular  
dECG  digital electrocardiogram  
E-R exposure -response  
ECG  electrocardiogram  
EClysis© user-interactive, modular computer -based system for dECG data processing, 
analysis and measurement of ECG intervals and wave amplitudes, exports and 
reports, used by [CONTACT_733765] C ase Report Form 
EEG  electroencephalogram  
FIH first in human  
FSH follicle stimulating hormone  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
GPCR  G protein -coupled receptor  
hERG  cardiac potassium ion channel  
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  77 of 78  
 Abbreviation or special 
term  Explanation  
HIV human immunodeficiency virus  
HL Hy’s Law  
HR heart rate 
IBBB  incomplete bundle branch block 
IC50 half maximal inhibitory concentration  
IC90 in vivo 90% inhibitory concentration 
ICF informed consent form 
ICH International Conference on Harmonisation  
IP investigational product  
IRB Institutional Review Board  
IVCD  intraventricular conduction delay  
LH luteinizing hormone  
NOAEL  no-observed -adverse -effect level  
NREM  non-rapid eye movement  
NSVT  non-sustained ventricular tachycardia  
OX1  orexin 1 receptor  
OX2  orexin 2 receptor  
PBPK  physiologically -based pharmacokinetic model  
PCI potentially clinically important 
PD pharmacodynamic  
pECG  paper electrocardiogram  
PK pharmacokinetic  
PopPK  population pharmacokinetic  
PR pulse rate  
PR(PQ)  ECG interval measured from the onset of the P wave to the onset of the QRS 
complex 
QRS  ECG interval measured from the onset of the QRS complex to the J point  
QT ECG interval measured from the onset of the QRS complex to the end of the T 
wave  
QTc corrected ECG Q -T interval  
QTcF  QT interval corrected for heart rate using Fridericia’s formula  
RR time elapsed between [ADDRESS_1002648] O perating Procedure 
Clinical Study Protocol Amendment 2 - 3.0 [COMPANY_008]  
AZD4041 - D7460C00001   
 
CONFIDENTIAL AND PROPRIETARY  78 of 78  
 Abbreviation or special 
term  Explanation  
SRC  Safety Review Committee  
TBL  total bilirubin  
t1/2λz terminal half -life 
Tmax time to reach maximum (peak) plasma concentration following drug 
administration  
ULN  upper limit of normal  
VPC  ventricular premature contraction  
Vss/F apparent volume of distribution at steady state after non-intravenous 
administration  
 